Search

Your search keyword '"A. Ávila Rivera"' showing total 238 results
Start Over Author "A. Ávila Rivera"
238 results on '"A. Ávila Rivera"'

2. Mapa epidemiológico transversal de las ataxias y paraparesias espásticas hereditarias en España

Author

G. Ortega Suero, M.J. Abenza Abildúa, C. Serrano Munuera, I. Rouco Axpe, F.J. Arpa Gutiérrez, A.D. Adarmes Gómez, F.J. Rodríguez de Rivera, B. Quintans Castro, I. Posada Rodríguez, A. Vadillo Bermejo, Á. Domingo Santos, E. Blanco Vicente, I. Infante Ceberio, J. Pardo Fernández, E. Costa Arpín, C. Painous Martí, J.E. Muñoz, P. Mir Rivera, F. Montón Álvarez, L. Bataller Alberola, J. Gascón Bayarri, C. Casasnovas Pons, V. Vélez Santamaría, A. López de Munain, G. Fernández-Eulate, J. Gazulla Abío, I. Sanz Gallego, L. Rojas Bartolomé, Ó. Ayo Martín, T. Segura Martín, C. González Mingot, M. Baraldés Rovira, R. Sivera Mascaró, E. Cubo Delgado, A. Echavarría Íñiguez, F. Vázquez Sánchez, M. Bártulos Iglesias, M.T. Casadevall Codina, E.M. Martínez Fernández, C. Labandeira Guerra, B. Alemany Perna, A. Carvajal Hernández, C. Fernández Moreno, M. Palacín Larroy, N. Caballol Pons, A. Ávila Rivera, F.J. Navacerrada Barrero, R. Lobato Rodríguez, and M.J. Sobrido Gómez

Subjects
Genetic map, Ataxia, Hereditary spastic paraplegia, Epidemiology, Genetics, Neurology. Diseases of the nervous system, RC346-429
Abstract

Resume: Introducción: Las ataxias (AT) y paraparesias espásticas hereditarias (PEH) son síndromes neurodegenerativos raros. Nos proponemos conocer la prevalencia de las AT y PEH en España en 2019. Pacientes y métodos: Estudio transversal, multicéntrico, descriptivo y retrospectivo de los pacientes con AT y PEH, desde marzo de 2018 a diciembre de 2019 en toda España. Resultados: Se obtuvo información de 1933 pacientes procedentes de 11 Comunidades Autónomas, de 47 neurólogos o genetistas. Edad media: 53,64 años ± 20,51 desviación estándar (DE); 938 varones (48,5%), 995 mujeres (51,5%). En 920 pacientes (47,6%) no se conoce el defecto genético. Por patologías, 1.371 pacientes (70,9%) diagnosticados de AT, 562 diagnosticados de PEH (29,1%). La prevalencia estimada de AT es 5,48/100.000 habitantes, y la de PEH es 2,24 casos/100.000 habitantes. La AT dominante más frecuente es la SCA3. La AT recesiva más frecuente es la ataxia de Friedreich (FRDA). La PEH dominante más frecuente es la SPG4, y la PEH recesiva más frecuente es la SPG7. Conclusiones: La prevalencia estimada de AT y PEH en nuestra serie es de 7,73 casos/100.000 habitantes. Estas frecuencias son similares a las del resto del mundo. En el 47,6% no se ha conseguido un diagnóstico genético. A pesar de las limitaciones, este estudio puede contribuir a estimar los recursos, visibilizar estas enfermedades, detectar las mutaciones más frecuentes para hacer los screenings por comunidades, y favorecer los ensayos clínicos. Abstract: Introduction: Ataxia and hereditary spastic paraplegia are rare neurodegenerative syndromes. We aimed to determine the prevalence of these disorders in Spain in 2019. Patients and methods: We conducted a cross-sectional, multicentre, retrospective, descriptive study of patients with ataxia and hereditary spastic paraplegia in Spain between March 2018 and December 2019. Results: We gathered data from a total of 1933 patients from 11 autonomous communities, provided by 47 neurologists or geneticists. Mean (SD) age in our sample was 53.64 (20.51) years; 938 patients were men (48.5%) and 995 were women (51.5%). The genetic defect was unidentified in 920 patients (47.6%). A total of 1371 patients (70.9%) had ataxia and 562 (29.1%) had hereditary spastic paraplegia. Prevalence rates for ataxia and hereditary spastic paraplegia were estimated at 5.48 and 2.24 cases per 100 000 population, respectively. The most frequent type of dominant ataxia in our sample was SCA3, and the most frequent recessive ataxia was Friedreich ataxia. The most frequent type of dominant hereditary spastic paraplegia in our sample was SPG4, and the most frequent recessive type was SPG7. Conclusions: In our sample, the estimated prevalence of ataxia and hereditary spastic paraplegia was 7.73 cases per 100 000 population. This rate is similar to those reported for other countries. Genetic diagnosis was not available in 47.6% of cases. Despite these limitations, our study provides useful data for estimating the necessary healthcare resources for these patients, raising awareness of these diseases, determining the most frequent causal mutations for local screening programmes, and promoting the development of clinical trials.

Published
2023
Full Text
View/download PDF

3. Epidemiology of ataxia and hereditary spastic paraplegia in Spain: A cross-sectional study

Author

G. Ortega Suero, M.J. Abenza Abildúa, C. Serrano Munuera, I. Rouco Axpe, F.J. Arpa Gutiérrez, A.D. Adarmes Gómez, F.J. Rodríguez de Rivera, B. Quintans Castro, I. Posada Rodríguez, A. Vadillo Bermejo, Á. Domingo Santos, E. Blanco Vicente, I. Infante Ceberio, J. Pardo Fernández, E. Costa Arpín, C. Painous Martí, J.E. Muñoz García, P. Mir Rivera, F. Montón Álvarez, L. Bataller Alberola, J. Gascón Bayarri, C. Casasnovas Pons, V. Vélez Santamaría, A. López de Munain, G. Fernández-Eulate, J. Gazulla Abío, I. Sanz Gallego, L. Rojas Bartolomé, Ó. Ayo Martín, T. Segura Martín, C. González Mingot, M. Baraldés Rovira, R. Sivera Mascaró, E. Cubo Delgado, A. Echavarría Íñiguez, F. Vázquez Sánchez, M. Bártulos Iglesias, M.T. Casadevall Codina, E.M. Martínez Fernández, C. Labandeira Guerra, B. Alemany Perna, A. Carvajal Hernández, C. Fernández Moreno, M. Palacín Larroy, N. Caballol Pons, A. Ávila Rivera, F.J. Navacerrada Barrero, R. Lobato Rodríguez, and M.J. Sobrido Gómez

Subjects
Mapa genético, Ataxias, Paraparesias espásticas hereditarias, Epidemiología, Genética, Neurology. Diseases of the nervous system, RC346-429
Abstract

Introduction: Ataxia and hereditary spastic paraplegia are rare neurodegenerative syndromes. We aimed to determine the prevalence of these disorders in Spain in 2019. Patients and methods: We conducted a cross-sectional, multicentre, retrospective, descriptive study of patients with ataxia and hereditary spastic paraplegia in Spain between March 2018 and December 2019. Results: We gathered data from a total of 1933 patients from 11 autonomous communities, provided by 47 neurologists or geneticists. Mean (SD) age in our sample was 53.64 (20.51) years; 938 patients were men (48.5%) and 995 were women (51.5%). The genetic defect was unidentified in 920 patients (47.6%). A total of 1371 patients (70.9%) had ataxia and 562 (29.1%) had hereditary spastic paraplegia. Prevalence rates for ataxia and hereditary spastic paraplegia were estimated at 5.48 and 2.24 cases per 100 000 population, respectively. The most frequent type of dominant ataxia in our sample was SCA3, and the most frequent recessive ataxia was Friedreich ataxia. The most frequent type of dominant hereditary spastic paraplegia in our sample was SPG4, and the most frequent recessive type was SPG7. Conclusions: In our sample, the estimated prevalence of ataxia and hereditary spastic paraplegia was 7.73 cases per 100 000 population. This rate is similar to those reported for other countries. Genetic diagnosis was not available in 47.6% of cases. Despite these limitations, our study provides useful data for estimating the necessary healthcare resources for these patients, raising awareness of these diseases, determining the most frequent causal mutations for local screening programmes, and promoting the development of clinical trials. Resumen: Introducción: Las ataxias (AT) y paraparesias espásticas hereditarias (PEH) son síndromes neurodegenerativos raros. Nos proponemos conocer la prevalencia de las AT y PEH (APEH) en España en 2019. Pacientes y métodos: Estudio transversal, multicéntrico, descriptivo y retrospectivo de los pacientes con AT y PEH, desde Marzo de 2018 a Diciembre de 2019 en toda España. Resultados: Se obtuvo información de 1.933 pacientes procedentes de 11 Comunidades Autónomas, de 47 neurólogos o genetistas. Edad media: 53,64 años ± 20,51 desviación estándar (DE); 938 varones (48,5%), 995 mujeres (51,1%). En 920 pacientes (47,6%) no se conoce el defecto genético. Por patologías, 1.371 pacientes (70,9%) diagnosticados de AT, 562 diagnosticados de PEH (29,1%). La prevalencia estimada de AT es 5,48/100.000 habitantes, y la de PEH es 2,24 casos/100.000 habitantes. La AT dominante más frecuente es la SCA3. La AT recesiva más frecuente es la ataxia de Friedreich (FRDA). La PEH dominante más frecuente es la SPG4, y la PEH recesiva más frecuente es la SPG7. Conclusiones: La prevalencia estimada de APEH en nuestra serie es de 7,73 casos/100.000 habitantes. Estas frecuencias son similares a las del resto del mundo. En el 47,6% no se ha conseguido un diagnóstico genético. A pesar de las limitaciones, este estudio puede contribuir a estimar los recursos, visibilizar estas enfermedades, detectar las mutaciones más frecuentes para hacer los screenings por comunidades, y favorecer los ensayos clínicos.

Published
2023
Full Text
View/download PDF

4. Cognitive impairment and dementia in young onset Parkinson’s disease

Author

Santos-García, Diego, de Deus Fonticoba, Teresa, Cores Bartolomé, Carlos, Feal Painceiras, María J., García Díaz, Iago, Íñiguez Alvarado, María Cristina, Paz, Jose Manuel, Jesús, Silvia, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Ines, Hernández Vara, Jorge, Cabo, Iria, López Manzanares, Lydia, González Aramburu, Isabel, Ávila Rivera, Maria A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Dotor García-Soto, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Mendoza, Zebenzui, Martínez Castrillo, Juan C., Sánchez Alonso, Pilar, Alonso Losada, Maria G., López Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Seijo, Manuel, Valero, Caridad, Alonso Redondo, Ruben, Buongiorno, Maria Teresa, Ordás, Carlos, Menéndez-González, Manuel, McAfee, Darrian, Martinez-Martin, Pablo, and Mir, Pablo

Published
2023
Full Text
View/download PDF

5. Staging Parkinson's disease according to the MNCD classification correlates with caregiver burden

Author

Diego Santos‐García, Teresa deDeus Fonticoba, Carlos Cores Bartolomé, María J. Feal Painceiras, Iago García Díaz, María Cristina Íñiguez Alvarado, Jose Manuel Paz, Silvia Jesús, Marina Cosgaya, Juan García Caldentey, Nuria Caballol, Ines Legarda, Jorge Hernández Vara, Iria Cabo, Lydia López Manzanares, Isabel González Aramburu, Maria A. Ávila Rivera, Víctor Gómez Mayordomo, Víctor Nogueira, Julio Dotor García‐Soto, Carmen Borrué, Berta Solano Vila, María Álvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Zebenzui Mendoza, Juan C. Martínez Castrillo, Pilar Sánchez Alonso, Maria G. Alonso Losada, Nuria López Ariztegui, Itziar Gastón, Jaime Kulisevsky, Manuel Seijo, Caridad Valero, Ruben Alonso Redondo, Maria Teresa Buongiorno, Carlos Ordás, Manuel Menéndez‐González, Darrian McAfee, Pablo Martinez‐Martin, Pablo Mir, and COPPADIS Study Group

Subjects
burden, caregiver, non‐motor symptoms, Parkinson's disease, stage, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Abstract

Abstract Background and objective Recently, we demonstrated that staging Parkinson's disease (PD) with a novel simple classification called MNCD, based on four axes (motor, non‐motor, cognition, and dependency) and five stages, correlated with disease severity and patients’ quality of life. Here, we analyzed the correlation of MNCD staging with PD caregiver's status. Patients and methods Data from the baseline visit of PD patients and their principal caregiver recruited from 35 centers in Spain from the COPPADIS cohort from January 2016 to November 2017 were used to apply the MNCD total score (from 0 to 12) and MNCD stages (from 1 to 5) in this cross‐sectional analysis. Caregivers completed the Zarit Caregiver Burden Inventory (ZCBI), Caregiver Strain Index (CSI), Beck Depression Inventory‐II (BDI‐II), PQ‐10, and EUROHIS‐QOL 8‐item index (EUROHIS‐QOL8). Results Two hundred and twenty‐four PD patients (63 ± 9.6 years old; 61.2% males) and their caregivers (58.5 ± 12.1 years old; 67.9% females) were included. The frequency of MNCD stages was 1, 7.6%; 2, 58.9%; 3, 31.3%; and 4–5, 2.2%. A more advanced MNCD stage was associated with a higher score on the ZCBI (p

Published
2023
Full Text
View/download PDF

6. Clinical utility of a personalized and long-term monitoring device for Parkinson's disease in a real clinical practice setting: An expert opinion survey on STAT-ON™

Author

Santos García, D., López Ariztegui, N., Cubo, E., Vinagre Aragón, A., García-Ramos, R., Borrué, C., Fernández-Pajarín, G., Caballol, N., Cabo, I., Barrios-López, J.M., Hernández Vara, J., Ávila Rivera, M.A., Gasca-Salas, C., Escalante, S., Manrique de Lara, P., Pérez Noguera, R., Álvarez Sauco, M., Sierra, M., Monje, M.H.G., Sánchez Ferro, A., Novo Ponte, S., Alonso-Frech, F., Macías-García, D., Legarda, I., Rojo, A., Álvarez Fernández, I., Buongiorno, M.T., Pastor, P., and García Ruíz, P.

Published
2023
Full Text
View/download PDF

7. Long-Term Real-World Experience with Safinamide in Patients with Parkinson's Disease.

Author

Planas-Ballvé, Anna, Caballol Pons, Núria, Peral Quirós, Alejandro, Gómez Ruiz, Isabel, Balagué Marmaña, Marta, Velázquez Ballester, Alexander J., Lozano Moreno, Dolors, and Ávila Rivera, Asunción

Subjects
PARKINSON'S disease, CLINICAL trials, TERMINATION of treatment, DOPAMINE agonists, MOVEMENT disorders
Abstract

Introduction: Randomized clinical trials should be complemented with data from real-world studies. We report our long-term experience with safinamide in a movement disorders unit. Methods: This retrospective study included patients with Parkinson's disease (PD) treated with safinamide in our unit from February 2016 to May 2022 under routine clinical practice. Assessments included the Hoehn and Yahr (HY) stage, unified Parkinson's disease rating scale (UPDRS) part III score, levodopa equivalent daily dose (LEDD), LEDD for dopamine agonists, and safinamide treatment discontinuation. Results: We included 180 patients with a median age of 74 years (IQR 11), and the majority (90.6%) had an HY stage of ≤2. After a median follow-up of 40 months (IQR 34), 14 patients discontinued treatment with safinamide (7.8%, 95% CI 4.7 to 12.6). Among the 166 patients who remained on safinamide, the UPDRS III score was stable (10 (IQR 9) vs. 9 (IQR 13), p = 0.455). The LEDD significantly increased from a median of 300 mg to 500 mg (p < 0.001), whereas the LEDD for dopamine agonists did not significantly increase. A subgroup of 89 patients who did not require dopamine agonists during follow-up showed stable UPDRS III score (10 (IQR 7) vs. 9 (IQR 14); p = 0.923), with a significant LEDD increase (300 mg to 400 mg, p < 0.001). Conclusions: Our results support the long-term effectiveness and tolerability of safinamide in patients with PD in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Predictors of clinically significant quality of life impairment in Parkinson’s disease

Author

Santos García D., Teresa de Deus Fonticoba, Carlos Cores, Guillermo Muñoz, Jose M. Paz González, Cristina Martínez Miró, Ester Suárez, Silvia Jesús, Miquel Aguilar, Pau Pastor, Lluis Planellas, Marina Cosgaya, Juan García Caldentey, Nuria Caballol, Inés Legarda, Jorge Hernández Vara, Iria Cabo, Luis López Manzanares, Isabel González Aramburu, María A. Ávila Rivera, Maria J. Catalán, Víctor Nogueira, Víctor Puente, María Ruíz de Arcos, Carmen Borrué, Berta Solano Vila, María Álvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Francisco Carrillo Padilla, Juan C. Martínez Castrillo, Pilar Sánchez Alonso, Maria G. Alonso Losada, Nuria López Ariztegui, Itziar Gastón, Pedro Clavero, Jaime Kulisevsky, Marta Blázquez Estrada, Manuel Seijo, Javier Rúiz Martínez, Caridad Valero, Mónica Kurtis, Oriol de Fábregues, Jessica González Ardura, Carlos Ordás, Luis M. López Díaz, Darrian McAfee, Pablo Martinez-Martin, Pablo Mir, and COPPADIS Study Group

Subjects
Neurology. Diseases of the nervous system, RC346-429
Abstract

Abstract Quality of life (QOL) plays an important role in independent living in Parkinson’s disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson’s disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p

Published
2021
Full Text
View/download PDF

10. Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression

Author

Santos-García, D., de Deus Fonticoba, T., Suárez Castro, E., Aneiros Díaz, A., Cores Bartolomé, C., Feal Panceiras, M.J., Paz González, J.M., Valdés Aymerich, L., García Moreno, J.M., Blázquez Estrada, M., Jesús, S., Mir, P., Aguilar, M., Planellas, L.L., García Caldentey, J., Caballol, N., Legarda, I., Cabo López, I., López Manzanares, L., Ávila Rivera, M.A., Catalán, M.J., López Díaz, L.M., Borrué, C., Álvarez Sauco, M., Vela, L., Cubo, E., Martínez Castrillo, J.C., Sánchez Alonso, P., Alonso Losada, M.G., López Ariztegui, N., Gastón, I., Pascual-Sedano, B., Seijo, M., Ruíz Martínez, J., Valero, C., Kurtis, M., González Ardura, J., Prieto Jurczynska, C., and Martinez-Martin, P.

Published
2020
Full Text
View/download PDF

12. Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson’s disease

Author

Martínez-Horta, Saul, Bejr-Kasem, Helena, Horta-Barba, Andrea, Pascual-Sedano, Berta, Santos-García, Diego, de Deus-Fonticoba, Teresa, Jesús, Silvia, Aguilar, Miquel, Planellas, Lluis, García-Caldentey, Juan, Caballol, Nuria, Vives-Pastor, Bárbara, Hernández-Vara, Jorge, Cabo-Lopez, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, Maria Asunción, Catalán, Maria Jose, López-Díaz, Luis Manuel, Puente, Victor, García-Moreno, Jose Manuel, Borrué, Carmen, Solano-Vila, Berta, Álvarez-Sauco, Maria, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo-Padilla, Francisco, Martínez-Castrillo, Juan Carlos, Sánchez-Alonso, Pilar, Alonso-Losada, Maria Gema, López-Ariztegui, Nuria, Gastón, Itziar, Blázquez-Estrada, Marta, Seijo-Martínez, Manual, Rúiz-Martínez, Javier, Valero-Merino, Caridad, Kurtis, Monica, de Fábregues-Boixar, Oriol, González-Ardura, Jessica, Prieto-Jurczynska, Cristina, Martinez-Martin, Pablo, Mir, Pablo, and Kulisevsky, Jaime

Published
2021
Full Text
View/download PDF

13. Staging Parkinson’s Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life

Author

D. Santos García, T. De Deus Fonticoba, J. M. Paz González, C. Cores Bartolomé, L. Valdés Aymerich, J. G. Muñoz Enríquez, E. Suárez, S. Jesús, M. Aguilar, P. Pastor, L. L. Planellas, M. Cosgaya, J. García Caldentey, N. Caballol, I. Legarda, J. Hernández Vara, I. Cabo, L. López Manzanares, I. González Aramburu, M. A. Ávila Rivera, M. J. Catalán, V. Nogueira, V. Puente, J. M. García Moreno, C. Borrué, B. Solano Vila, M. Álvarez Sauco, L. Vela, S. Escalante, E. Cubo, F. Carrillo Padilla, J. C. Martínez Castrillo, P. Sánchez Alonso, M. G. Alonso Losada, N. López Ariztegui, I. Gastón, J. Kulisevsky, M. Blázquez Estrada, M. Seijo, J. Rúiz Martínez, C. Valero, M. Kurtis, O. de Fábregues, J. González Ardura, C. Ordás, L. López Díaz, P. Mir, P. Martinez-Martin, and COPPADIS Study Group

Subjects
Neurology. Diseases of the nervous system, RC346-429
Abstract

Introduction. In a degenerative disorder such as Parkinson’s disease (PD), it is important to establish clinical stages that allow to know the course of the disease. Our aim was to analyze whether a scale combining Hoehn and Yahr’s motor stage (H&Y) and the nonmotor symptoms burden (NMSB) (assessed by the nonmotor symptoms scale (NMSS)) provides information about the disability and the patient’s quality of life (QoL) with regard to a defined clinical stage. Materials and Methods. Cross-sectional study in which 603 PD patients from the COPPADIS cohort were classified according to H&Y (1, stage I; 2, stage II; 3, stage III; 4, stage IV/V) and NMSB (A: NMSS = 0–20; B: NMSS = 21–40; C: NMSS = 41–70; D: NMSS ≥ 71) in 16 stages (HY.NMSB, from 1A to 4D). QoL was assessed with the PDQ-39SI, PQ-10, and EUROHIS-QOL8 and disability with the Schwab&England ADL (Activities of Daily Living) scale. Results. A worse QoL and greater disability were observed at a higher stage of H&Y and NMSB (p

Published
2021
Full Text
View/download PDF

14. Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson’s Disease Patients: A 2-Year Follow-Up Study

Author

Diego Santos-García, Teresa de Deus Fonticoba, Carlos Cores Bartolomé, Maria J. Feal Painceiras, Ester Suárez Castro, Héctor Canfield, Cristina Martínez Miró, Silvia Jesús, Miquel Aguilar, Pau Pastor, Lluís Planellas, Marina Cosgaya, Juan García Caldentey, Nuria Caballol, Ines Legarda, Jorge Hernández-Vara, Iria Cabo, Lydia López Manzanares, Isabel González Aramburu, Maria A. Ávila Rivera, Víctor Gómez Mayordomo, Víctor Nogueira, Víctor Puente, Julio Dotor García-Soto, Carmen Borrué, Berta Solano Vila, María Álvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Francisco Carrillo Padilla, Juan C. Martínez Castrillo, Pilar Sánchez Alonso, Maria G. Alonso Losada, Nuria López Ariztegui, Itziar Gastón, Jaime Kulisevsky, Marta Blázquez Estrada, Manuel Seijo, Javier Rúiz Martínez, Caridad Valero, Mónica Kurtis, Oriol de Fábregues, Jessica González Ardura, Ruben Alonso Redondo, Carlos Ordás, Luis M. López Díaz, Darrian McAfee, Pablo Martinez-Martin, Pablo Mir, and COPPADIS Study Group

Subjects
burden, follow-up, non-motor symptoms, motor fluctuations, Parkinson’s disease, Medicine (General), R5-920
Abstract

Objective: The aim of the present study was to analyze the progression of non-motor symptoms (NMS) burden in Parkinson’s disease (PD) patients regarding the development of motor fluctuations (MF). Methods: PD patients without MF at baseline, who were recruited from January 2016 to November 2017 (V0) and evaluated again at a 2-year follow-up (V2) from 35 centers of Spain from the COPPADIS cohort, were included in this analysis. MF development at V2 was defined as a score ≥ 1 in the item-39 of the UPDRS-Part IV, whereas NMS burden was defined according to the Non-motor Symptoms Scale (NMSS) total score. Results: Three hundred and thirty PD patients (62.67 ± 8.7 years old; 58.8% males) were included. From V0 to V2, 27.6% of the patients developed MF. The mean NMSS total score at baseline was higher in those patients who developed MF after the 2-year follow-up (46.34 ± 36.48 vs. 34.3 ± 29.07; p = 0.001). A greater increase in the NMSS total score from V0 to V2 was observed in patients who developed MF (+16.07 ± 37.37) compared to those who did not develop MF (+6.2 ± 25.8) (p = 0.021). Development of MF after a 2-year follow-up was associated with an increase in the NMSS total score (β = 0.128; p = 0.046) after adjustment to age, gender, years from symptoms onset, levodopa equivalent daily dose (LEDD) and the NMSS total score at baseline, and the change in LEDD from V0 to V2. Conclusions: In PD patients, the development of MF is associated with a greater increase in the NMS burden after a 2-year follow-up.

Published
2022
Full Text
View/download PDF

15. Response to levodopa in Parkinson's disease over time. A 4-year follow-up study

Author

Santos-García, Diego, primary, de Deus Fonticoba, Teresa, additional, Cores Bartolomé, Carlos, additional, Feal Painceiras, María J., additional, García Díaz, Iago, additional, Íñiguez Alvarado, María Cristina, additional, Paz, Jose Manuel, additional, Jesús, Silvia, additional, Cosgaya, Marina, additional, García Caldentey, Juan, additional, Caballol, Nuria, additional, Legarda, Ines, additional, González Aramburu, Isabel, additional, Ávila Rivera, Maria A., additional, Gómez Mayordomo, Víctor, additional, Vela, Lydia, additional, Escalante, Sonia, additional, Mendoza, Zebenzui, additional, Martínez Castrillo, Juan C., additional, Alonso, Pilar Sánchez, additional, Alonso Losada, Maria G., additional, López Ariztegui, Nuria, additional, McAfee, Darrian, additional, Martinez-Martin, Pablo, additional, and Mir, Pablo, additional

Published
2023
Full Text
View/download PDF

16. Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up

Author

Diego Santos García, Lucía Naya Ríos, Teresa de Deus Fonticoba, Carlos Cores Bartolomé, Lucía García Roca, Maria Feal Painceiras, Cristina Martínez Miró, Hector Canfield, Silvia Jesús, Miquel Aguilar, Pau Pastor, Marina Cosgaya, Juan García Caldentey, Nuria Caballol, Inés Legarda, Jorge Hernández Vara, Iria Cabo, Lydia López Manzanares, Isabel González Aramburu, María A. Ávila Rivera, Víctor Gómez Mayordomo, Víctor Nogueira, Víctor Puente, Julio Dotor, Carmen Borrué, Berta Solano Vila, María Álvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Francisco Carrillo Padilla, Juan C. Martínez Castrillo, Pilar Sánchez Alonso, Maria G. Alonso Losada, Nuria López Ariztegui, Itziar Gastón, Jaime Kulisevsky, Marta Blázquez Estrada, Manuel Seijo, Javier Rúiz Martínez, Caridad Valero, Mónica Kurtis, Oriol de Fábregues, Jessica González Ardura, Ruben Alonso Redondo, Carlos Ordás, Luis M. López Díaz, Darrian McAfee, Pablo Martinez-Martin, and Pablo Mir

Subjects
changes, motor, Parkinson’s disease, phenotype, PIGD, Tremor, Medicine (General), R5-920
Abstract

Background and objective: Diplopia is relatively common in Parkinson’s disease (PD) but is still understudied. Our aim was to analyze the frequency of diplopia in PD patients from a multicenter Spanish cohort, to compare the frequency with a control group, and to identify factors associated with it. Patients and Methods: PD patients who were recruited from January 2016 to November 2017 (baseline visit; V0) and evaluated again at a 2-year ± 30 days follow-up (V2) from 35 centers of Spain from the COPPADIS cohort were included in this longitudinal prospective study. The patients and controls were classified as “with diplopia” or “without diplopia” according to item 15 of the Non-Motor Symptoms Scale (NMSS) at V0, V1 (1-year ± 15 days), and V2 for the patients and at V0 and V2 for the controls. Results: The frequency of diplopia in the PD patients was 13.6% (94/691) at V0 (1.9% in controls [4/206]; p < 0.0001), 14.2% (86/604) at V1, and 17.1% (86/502) at V2 (0.8% in controls [1/124]; p < 0.0001), with a period prevalence of 24.9% (120/481). Visual hallucinations at any visit from V0 to V2 (OR = 2.264; 95%CI, 1.269–4.039; p = 0.006), a higher score on the NMSS at V0 (OR = 1.009; 95%CI, 1.012–1.024; p = 0.015), and a greater increase from V0 to V2 on the Unified Parkinson’s Disease Rating Scale–III (OR = 1.039; 95%CI, 1.023–1.083; p < 0.0001) and Neuropsychiatric Inventory (OR = 1.028; 95%CI, 1.001–1.057; p = 0.049) scores were independent factors associated with diplopia (R2 = 0.25; Hosmer and Lemeshow test, p = 0.716). Conclusions: Diplopia represents a frequent symptom in PD patients and is associated with motor and non-motor severity.

Published
2021
Full Text
View/download PDF

17. Predictors of Loss of Functional Independence in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group

Author

Diego Santos García, Teresa de Deus Fonticoba, Carlos Cores Bartolomé, Lucía Naya Ríos, Lucía García Roca, Cristina Martínez Miró, Hector Canfield, Silvia Jesús, Miquel Aguilar, Pau Pastor, Marina Cosgaya, Juan García Caldentey, Nuria Caballol, Inés Legarda, Jorge Hernández Vara, Iria Cabo, Lydia López Manzanares, Isabel González Aramburu, María A. Ávila Rivera, Víctor Gómez Mayordomo, Víctor Nogueira, Víctor Puente, Julio Dotor, Carmen Borrué, Berta Solano Vila, María Álvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Francisco Carrillo Padilla, Juan C. Martínez Castrillo, Pilar Sánchez Alonso, Maria G. Alonso Losada, Nuria López Ariztegui, Itziar Gastón, Jaime Kulisevsky, Marta Blázquez Estrada, Manuel Seijo, Javier Rúiz Martínez, Caridad Valero, Mónica Kurtis, Oriol de Fábregues, Jessica González Ardura, Ruben Alonso Redondo, Carlos Ordás, Luis M. López Díaz, Darrian McAfee, Pablo Martinez-Martin, Pablo Mir, and COPPADIS Study Group

Subjects
activities of daily living, dependency, disability, gait, Parkinson’s disease, Medicine (General), R5-920
Abstract

Background and objective: The aim of this study was to compare the progression of independence in activities of daily living (ADL) in Parkinson’s disease (PD) patients versus a control group, as well as to identify predictors of disability progression and functional dependency (FD). Patients and Methods: PD patients and control subjects, who were recruited from 35 centers of Spain from the COPPADIS cohort between January 2016 and November 2017 (V0), were included. Patients and subjects were then evaluated again at the 2-year follow-up (V2). Disability was assessed with the Schwab & England Activities of Daily Living Scale (S&E-ADLS) at V0 and V2. FD was defined as an S&E-ADLS score less than 80%. Results: In the PD group, a significant decrease in the S&E-ADLS score from V0 to V2 (N = 507; from 88.58 ± 10.19 to 84.26 ± 13.38; p < 0.0001; Cohen’s effect size = −0.519) was observed but not in controls (N = 124; from 98.87 ± 6.52 to 99.52 ± 2.15; p = 0.238). When only patients considered functional independent at baseline were included, 55 out of 463 (11.9%) converted to functional dependent at V2. To be a female (OR = 2.908; p = 0.009), have longer disease duration (OR = 1.152; p = 0.002), have a non-tremoric motor phenotype at baseline (OR = 3.574; p = 0.004), have a higher score at baseline in FOGQ (OR = 1.244; p < 0.0001) and BDI-II (OR = 1.080; p = 0.008), have a lower score at baseline in PD-CRS (OR = 0.963; p = 0.008), and have a greater increase in the score from V0 to V2 in UPDRS-IV (OR = 1.168; p = 0.0.29), FOGQ (OR = 1.348; p < 0.0001) and VAFS-Mental (OR = 1.177; p = 0.013) (adjusted R-squared 0.52; Hosmer and Lemeshow test = 0.94) were all found to be independent predictors of FD at V2. Conclusions: In conclusion, autonomy for ADL worsens in PD patients compared to controls. Cognitive impairment, gait problems, fatigue, depressive symptoms, more advanced disease, and a non-tremor phenotype are independent predictors of FD in the short-term.

Published
2021
Full Text
View/download PDF

18. Mapa epidemiológico transversal de las ataxias y paraparesias espásticas hereditarias en España

Author

Ortega Suero, G., primary, Abenza Abildúa, M.J., additional, Serrano Munuera, C., additional, Rouco Axpe, I., additional, Arpa Gutiérrez, F.J., additional, Adarmes Gómez, A.D., additional, Rodríguez de Rivera, F.J., additional, Quintans Castro, B., additional, Posada Rodríguez, I., additional, Vadillo Bermejo, A., additional, Domingo Santos, Á., additional, Blanco Vicente, E., additional, Infante Ceberio, I., additional, Pardo Fernández, J., additional, Costa Arpín, E., additional, Painous Martí, C., additional, Muñoz, J.E., additional, Mir Rivera, P., additional, Montón Álvarez, F., additional, Bataller Alberola, L., additional, Gascón Bayarri, J., additional, Casasnovas Pons, C., additional, Vélez Santamaría, V., additional, López de Munain, A., additional, Fernández-Eulate, G., additional, Gazulla Abío, J., additional, Sanz Gallego, I., additional, Rojas Bartolomé, L., additional, Ayo Martín, Ó., additional, Segura Martín, T., additional, González Mingot, C., additional, Baraldés Rovira, M., additional, Sivera Mascaró, R., additional, Cubo Delgado, E., additional, Echavarría Íñiguez, A., additional, Vázquez Sánchez, F., additional, Bártulos Iglesias, M., additional, Casadevall Codina, M.T., additional, Martínez Fernández, E.M., additional, Labandeira Guerra, C., additional, Alemany Perna, B., additional, Carvajal Hernández, A., additional, Fernández Moreno, C., additional, Palacín Larroy, M., additional, Caballol Pons, N., additional, Ávila Rivera, A., additional, Navacerrada Barrero, F.J., additional, Lobato Rodríguez, R., additional, and Sobrido Gómez, M.J., additional

Published
2023
Full Text
View/download PDF

19. Epidemiology of ataxia and hereditary spastic paraplegia in Spain: A cross-sectional study

Author

Ortega Suero, G., primary, Abenza Abildúa, M.J., additional, Serrano Munuera, C., additional, Rouco Axpe, I., additional, Arpa Gutiérrez, F.J., additional, Adarmes Gómez, A.D., additional, Rodríguez de Rivera, F.J., additional, Quintans Castro, B., additional, Posada Rodríguez, I., additional, Vadillo Bermejo, A., additional, Domingo Santos, Á., additional, Blanco Vicente, E., additional, Infante Ceberio, I., additional, Pardo Fernández, J., additional, Costa Arpín, E., additional, Painous Martí, C., additional, Muñoz García, J.E., additional, Mir Rivera, P., additional, Montón Álvarez, F., additional, Bataller Alberola, L., additional, Gascón Bayarri, J., additional, Casasnovas Pons, C., additional, Vélez Santamaría, V., additional, López de Munain, A., additional, Fernández-Eulate, G., additional, Gazulla Abío, J., additional, Sanz Gallego, I., additional, Rojas Bartolomé, L., additional, Ayo Martín, Ó., additional, Segura Martín, T., additional, González Mingot, C., additional, Baraldés Rovira, M., additional, Sivera Mascaró, R., additional, Cubo Delgado, E., additional, Echavarría Íñiguez, A., additional, Vázquez Sánchez, F., additional, Bártulos Iglesias, M., additional, Casadevall Codina, M.T., additional, Martínez Fernández, E.M., additional, Labandeira Guerra, C., additional, Alemany Perna, B., additional, Carvajal Hernández, A., additional, Fernández Moreno, C., additional, Palacín Larroy, M., additional, Caballol Pons, N., additional, Ávila Rivera, A., additional, Navacerrada Barrero, F.J., additional, Lobato Rodríguez, R., additional, and Sobrido Gómez, M.J., additional

Published
2023
Full Text
View/download PDF

20. Suicidal ideation among people with Parkinson's disease and comparison with a control group

Author

Fundación Centro de Investigación de Enfermedades Neurológicas, Alpha Bioresearch, Instituto de Salud Carlos III, Santos-García, Diego [0000-0002-3126-5111], Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., García Díaz, Iago, Íñiguez-Alvarado, María Cristina, Jesús Maestre, Silvia, Buongiorno, Maria Teresa, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Puente, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Blázquez-Estrada, Marta, Seijo, Manuel, Ruiz Martínez, Javier, Valero, Caridad, Kurtis, Mónica, Fábregues-Boixar, Oriol de, González Ardura, Jessica, Alonso Redondo, Rubén, Ordás, Carlos, López-Díaz, Luis M., McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, Fundación Centro de Investigación de Enfermedades Neurológicas, Alpha Bioresearch, Instituto de Salud Carlos III, Santos-García, Diego [0000-0002-3126-5111], Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., García Díaz, Iago, Íñiguez-Alvarado, María Cristina, Jesús Maestre, Silvia, Buongiorno, Maria Teresa, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Puente, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Blázquez-Estrada, Marta, Seijo, Manuel, Ruiz Martínez, Javier, Valero, Caridad, Kurtis, Mónica, Fábregues-Boixar, Oriol de, González Ardura, Jessica, Alonso Redondo, Rubén, Ordás, Carlos, López-Díaz, Luis M., McAfee, Darrian, Martínez-Martín, Pablo, and Mir, Pablo

Abstract

[Background] Detection of suicidal ideation (SI) is key for trying to prevent suicide. The aim of this study was to analyze the frequency of SI and related factors in Spanish people with Parkinson's Disease (PwPD) and to compare them with a control group., [Methods] PD patients and controls recruited from the Spanish cohort COPPADIS from January 2016 to November 2017 were included. Two visits were conducted: V0 (baseline); V2 (2-year ± 1 month follow-up). SI was defined as a score ≥1 on item nine of the Beck Depression Inventory-II (BDI-II). Regression analyses were conducted to identify factors related to SI., [Results] At baseline, 693 PwPD (60.2% males; 62.59 ± 8.91 years old) and 207 controls (49.8% males; 60.99 ± 8.32 years old) were included. No differences between PwPD and controls were detected in SI frequency at either V0 (5.1% [35/693] vs. 4.3% [9/207]; p = 0.421) or at V2 (5.1% [26/508] vs. 4.8% [6/125]; p = 0.549). Major depression (MD) and a worse quality of life were associated with SI at both visits in PwPD: V0 (MD, OR = 5.63; p = 0.003; PDQ-39, OR = 1.06; p = 0.021); V2 (MD, OR = 4.75; p = 0.027; EUROHIS-QOL8, OR = 0.22; p = 0.006). A greater increase in the BDI-II total score from V0 to V2 was the only factor predicting SI at V2 (OR = 1.21; p = 0.002) along with an increase in the total number of non-antiparkinsonian drugs (OR = 1.39; p = 0.041)., [Conclusion] The frequency of SI (5%) in PwPD was similar to in controls. Depression, a worse quality of life, and a greater comorbidity were related to SI.

Published
2023

21. Sex Differences in Motor and Non-Motor Symptoms among Spanish Patients with Parkinson's Disease

Author

Fundación Centro de Investigación de Enfermedades Neurológicas, Alpha Bioresearch, Instituto de Salud Carlos III, Santos-García, Diego [0000-0002-3126-5111], Laguna, Ariadna [0000-0002-9732-6677], Hernández-Vara, Jorge [0000-0002-9129-5224], Cores Bartolomé, Carlos [0000-0002-8352-2263], García Díaz, Iago [0000-0003-3304-0714], Cabo, Iria [0000-0003-2436-6499], González-Aramburu, Isabel [0000-0002-3696-4093], Gómez Mayordomo, Víctor [0000-0001-9343-8439], Martínez-Castrillo, J. C. [0000-0001-7744-6850], Sánchez Alonso, Pilar [0000-0003-0496-4707], López-Ariztegui, Nuria [0000-0001-7172-3191], Menéndez-González, Manuel [0000-0002-5218-0774], Martínez-Martín, Pablo [0000-0003-0837-5280], Mir, Pablo [0000-0003-1656-302X], Santos-García, Diego, Laguna, Ariadna, Hernández-Vara, Jorge, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., Íñiguez-Alvarado, María Cristina, García Díaz, Iago, Jesús Maestre, Silvia, Buongiorno, Maria Teresa, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Puente, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Menéndez-González, Manuel, Seijo, Manuel, Ruiz Martínez, Javier, Valero, Caridad, Kurtis, Mónica, González Ardura, Jessica, Alonso Redondo, Rubén, Ordás, Carlos, López-Díaz, Luis M., McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, COPPADIS Study Group, Fundación Centro de Investigación de Enfermedades Neurológicas, Alpha Bioresearch, Instituto de Salud Carlos III, Santos-García, Diego [0000-0002-3126-5111], Laguna, Ariadna [0000-0002-9732-6677], Hernández-Vara, Jorge [0000-0002-9129-5224], Cores Bartolomé, Carlos [0000-0002-8352-2263], García Díaz, Iago [0000-0003-3304-0714], Cabo, Iria [0000-0003-2436-6499], González-Aramburu, Isabel [0000-0002-3696-4093], Gómez Mayordomo, Víctor [0000-0001-9343-8439], Martínez-Castrillo, J. C. [0000-0001-7744-6850], Sánchez Alonso, Pilar [0000-0003-0496-4707], López-Ariztegui, Nuria [0000-0001-7172-3191], Menéndez-González, Manuel [0000-0002-5218-0774], Martínez-Martín, Pablo [0000-0003-0837-5280], Mir, Pablo [0000-0003-1656-302X], Santos-García, Diego, Laguna, Ariadna, Hernández-Vara, Jorge, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., Íñiguez-Alvarado, María Cristina, García Díaz, Iago, Jesús Maestre, Silvia, Buongiorno, Maria Teresa, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Puente, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Menéndez-González, Manuel, Seijo, Manuel, Ruiz Martínez, Javier, Valero, Caridad, Kurtis, Mónica, González Ardura, Jessica, Alonso Redondo, Rubén, Ordás, Carlos, López-Díaz, Luis M., McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, and COPPADIS Study Group

Abstract

[Background and objective] Sex plays a role in Parkinson's disease (PD) mechanisms. We analyzed sex difference manifestations among Spanish patients with PD., [Patients and Methods] PD patients who were recruited from the Spanish cohort COPPADIS from January 2016 to November 2017 were included. A cross-sectional and a two-year follow-up analysis were conducted. Univariate analyses and general linear model repeated measure were used., [Results] Results: At baseline, data from 681 PD patients (mean age 62.54 ± 8.93) fit the criteria for analysis. Of them, 410 (60.2%) were males and 271 (39.8%) females. There were no differences between the groups in mean age (62.36 ± 8.73 vs. 62.8 ± 9.24; p = 0.297) or in the time from symptoms onset (5.66 ± 4.65 vs. 5.21 ± 4.11; p = 0.259). Symptoms such as depression (p < 0.0001), fatigue (p < 0.0001), and pain (p < 0.00001) were more frequent and/or severe in females, whereas other symptoms such as hypomimia (p < 0.0001), speech problems (p < 0.0001), rigidity (p < 0.0001), and hypersexuality (p < 0.0001) were more noted in males. Women received a lower levodopa equivalent daily dose (p = 0.002). Perception of quality of life was generally worse in females (PDQ-39, p = 0.002; EUROHIS-QOL8, p = 0.009). After the two-year follow-up, the NMS burden (Non-Motor Symptoms Scale total score) increased more significantly in males (p = 0.012) but the functional capacity (Schwab and England Activities of Daily Living Scale) was more impaired in females (p = 0.001)., [Conclusion] The present study demonstrates that there are important sex differences in PD. Long-term prospective comparative studies are needed.

Published
2023

22. Falls Predict Acute Hospitalization in Parkinson's Disease

Author

Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Suárez Castro, Ester, Hernández-Vara, Jorge, Jesús Maestre, Silvia, Mir, Pablo, Cosgaya, Marina, Martí, María-José, Pastor, Pau, Cabo, Iria, Seijo, Manuel, Legarda, Inés, Vives, Bárbara, Caballol, Nuria, Ruiz Martínez, Javier, Croitoru, Ioana, Cubo, Esther, Miranda, Javier, Alonso Losada, María G., Labandeira, Carmen, López-Ariztegui, Nuria, Morales Casado, M. I., González-Aramburu, Isabel, Infante, Jon, Escalante, Sonia, Bernardo, Noemí, Blázquez-Estrada, Marta, Menéndez-González, Manuel, García Caldentey, Juan, Borrué, Carmen, Vela, Lydia, Catalán, Maria José, Gómez Mayordomo, Víctor, Kurtis, Mónica, Prieto López, Cristina, Ordás, Carlos, Nogueira, Víctor, López-Manzanares, Lydia, Ávila-Rivera, María A., Puente, Víctor, García Moreno, J. M., Solano Vila, Berta, Álvarez-Sauco, María, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Gastón, Itziar, Kulisevsky, Jaime, Valero, Caridad, Fábregues-Boixar, Oriol de, González Ardura, Jessica, López-Díaz, Luis M., Martínez-Martín, Pablo, Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Suárez Castro, Ester, Hernández-Vara, Jorge, Jesús Maestre, Silvia, Mir, Pablo, Cosgaya, Marina, Martí, María-José, Pastor, Pau, Cabo, Iria, Seijo, Manuel, Legarda, Inés, Vives, Bárbara, Caballol, Nuria, Ruiz Martínez, Javier, Croitoru, Ioana, Cubo, Esther, Miranda, Javier, Alonso Losada, María G., Labandeira, Carmen, López-Ariztegui, Nuria, Morales Casado, M. I., González-Aramburu, Isabel, Infante, Jon, Escalante, Sonia, Bernardo, Noemí, Blázquez-Estrada, Marta, Menéndez-González, Manuel, García Caldentey, Juan, Borrué, Carmen, Vela, Lydia, Catalán, Maria José, Gómez Mayordomo, Víctor, Kurtis, Mónica, Prieto López, Cristina, Ordás, Carlos, Nogueira, Víctor, López-Manzanares, Lydia, Ávila-Rivera, María A., Puente, Víctor, García Moreno, J. M., Solano Vila, Berta, Álvarez-Sauco, María, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Gastón, Itziar, Kulisevsky, Jaime, Valero, Caridad, Fábregues-Boixar, Oriol de, González Ardura, Jessica, López-Díaz, Luis M., and Martínez-Martín, Pablo

Abstract

[Background] There is a need for identifying risk factors for hospitalization in Parkinson’s disease (PD) and also interventions to reduce acute hospital admission., [Objective] To analyze the frequency, causes, and predictors of acute hospitalization (AH) in PD patients from a Spanish cohort., [Methods] PD patients recruited from 35 centers of Spain from the COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015) cohort from January 2016 to November 2017, were included in the study. In order to identify predictors of AH, Kaplan-Meier estimates of factors considered as potential predictors were obtained and Cox regression performed on time to hospital encounter 1-year after the baseline visit., [Results] Thirty-five out of 605 (5.8%) PD patients (62.5±8.9 years old; 59.8% males) presented an AH during the 1-year follow-up after the baseline visit. Traumatic falls represented the most frequent cause of admission, being 23.7% of all acute hospitalizations. To suffer from motor fluctuations (HR [hazard ratio] 2.461; 95% CI, 1.065–5.678; p = 0.035), a very severe non-motor symptoms burden (HR [hazard ratio] 2.828; 95% CI, 1.319–6.063; p = 0.008), falls (HR 3.966; 95% CI 1.757–8.470; p = 0.001), and dysphagia (HR 2.356; 95% CI 1.124–4.941; p = 0.023) was associated with AH after adjustment to age, gender, disease duration, levodopa equivalent daily dose, total number of non-antiparkinsonian drugs, and UPDRS-IIIOFF. Of the previous variables, only falls (HR 2.998; 95% CI 1.080–8.322; p = 0.035) was an independent predictor of AH., [Conclusion] Falls is an independent predictor of AH in PD patients.

Published
2023

23. Risk of Cognitive Impairment in Patients With Parkinson’s Disease With Visual Hallucinations and Subjective Cognitive Complaints

Author

Fundación Degen, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., Paz González, J. M., Martínez Miró, Cristina, Jesús Maestre, Silvia, Aguilar, Miquel, Pastor, Pau, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Maria A. Ávila Rivera,o, Gómez Mayordomo, Víctor, Nogueira, Víctor, Puente, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Blázquez-Estrada, Marta, Seijo, Manuel, Ruiz Martínez, Javier, Valero, Caridad, Kurtis, Mónica, Fábregues-Boixar, Oriol de, González Ardura, Jessica, Alonso Redondo, Rubén, Ordás, Carlos, López-Díaz, Luis M., McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, COPPADIS Study Group, Fundación Degen, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., Paz González, J. M., Martínez Miró, Cristina, Jesús Maestre, Silvia, Aguilar, Miquel, Pastor, Pau, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Maria A. Ávila Rivera,o, Gómez Mayordomo, Víctor, Nogueira, Víctor, Puente, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Blázquez-Estrada, Marta, Seijo, Manuel, Ruiz Martínez, Javier, Valero, Caridad, Kurtis, Mónica, Fábregues-Boixar, Oriol de, González Ardura, Jessica, Alonso Redondo, Rubén, Ordás, Carlos, López-Díaz, Luis M., McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, and COPPADIS Study Group

Abstract

[Background and Purpose] Visual hallucinations (VH) and subjective cognitive complaints (SCC) are associated with cognitive impairment (CI) in Parkinson’s disease. Our aims were to determine the association between VH and SCC and the risk of CI development in a cohort of patients with Parkinson’s disease and normal cognition (PD-NC)., [Methods] Patients with PD-NC (total score of >80 on the Parkinson’s Disease Cognitive Rating Scale [PD-CRS]) recruited from the Spanish COPPADIS cohort from January 2016 to November 2017 were followed up after 2 years. Subjects with a score of ≥1 on domain 5 and item 13 of the Non-Motor Symptoms Scale at baseline (V0) were considered as “with SCC” and “with VH,” respectively. CI at the 2-year follow-up (plus or minus 1 month) (V2) was defined as a PD-CRS total score of <81., [Results] At V0 (n=376, 58.2% males, age 61.14±8.73 years [mean±SD]), the frequencies of VH and SCC were 13.6% and 62.2%, respectively. VH were more frequent in patients with SCC than in those without: 18.8% (44/234) vs 4.9% (7/142), p<0.0001. At V2, 15.2% (57/376) of the patients had developed CI. VH presenting at V0 was associated with a higher risk of CI at V2 (odds ratio [OR]=2.68, 95% confidence interval=1.05–6.83, p=0.0.039) after controlling for the effects of age, disease duration, education, medication, motor and nonmotor status, mood, and PD-CRS total score at V0. Although SCC were not associated with CI at V2, presenting both VH and SCC at V0 increased the probability of having CI at V2 (OR=3.71, 95% confidence interval=1.36–10.17, p=0.011)., [Conclusions] VH were associated with the development of SCC and CI at the 2-year follow-up in patients with PD-NC.

Published
2023

24. Staging Parkinson’s Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life

Author

Fundación Degen, Alpha Bioresearch, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., Íñiguez-Alvarado, María Cristina, García Díaz, Iago, Jesús Maestre, Silvia, Buongiorno, Maria Teresa, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Puente, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Menéndez-González, Manuel, Seijo, Manuel, Ruiz Martínez, Javier, Valero, Caridad, Kurtis, Mónica, González Ardura, Jessica, Alonso Redondo, Rubén, Ordás, Carlos, López-Díaz, Luis M., McAfee, Darrian, Calopa, Matildeoo, Carrillo, Fátima, Escamilla-Sevilla, Francisco, Freire, Eric, Gómez Esteban, Juan Carlos, García-Ramos, Rocío, Luquín, María Rosario Isabel, Martínez Torres, Irene, Sesar Ignacio, Ángel, Martínez-Martín, Pablo, Mir, Pablo, COPPADIS Study Group, Fundación Degen, Alpha Bioresearch, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., Íñiguez-Alvarado, María Cristina, García Díaz, Iago, Jesús Maestre, Silvia, Buongiorno, Maria Teresa, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Puente, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Menéndez-González, Manuel, Seijo, Manuel, Ruiz Martínez, Javier, Valero, Caridad, Kurtis, Mónica, González Ardura, Jessica, Alonso Redondo, Rubén, Ordás, Carlos, López-Díaz, Luis M., McAfee, Darrian, Calopa, Matildeoo, Carrillo, Fátima, Escamilla-Sevilla, Francisco, Freire, Eric, Gómez Esteban, Juan Carlos, García-Ramos, Rocío, Luquín, María Rosario Isabel, Martínez Torres, Irene, Sesar Ignacio, Ángel, Martínez-Martín, Pablo, Mir, Pablo, and COPPADIS Study Group

Abstract

Background: Recently, a novel simple classification called MNCD, based on 4 axes (Motor; Non-motor; Cognition; Dependency) and 5 stages, has been proposed to classify Parkinson's disease (PD)., Objective: Our aim was to apply the MNCD classification in a cohort of PD patients for the first time and also to analyze the correlation with quality of life (QoL) and disease severity., Methods: Data from the baseline visit of PD patients recruited from 35 centers in Spain from the COPPADIS cohort fromJanuary 2016 to November 2017 were used to apply the MNCD classification. Three instruments were used to assess QoL:1) the 39-item Parkinson's disease Questionnaire [PDQ-39]); PQ-10; the EUROHIS-QOL 8-item index (EUROHIS-QOL8)., Results: Four hundred and thirty-nine PD patients (62.05±7.84 years old; 59% males) were included. MNCD stage was:stage 1, 8.4% (N = 37); stage 2, 62% (N = 272); stage 3, 28.2% (N = 124); stage 4-5, 1.4% (N = 6). A more advancedMNCD stage was associated with a higher score on the PDQ39SI (p < 0.0001) and a lower score on the PQ-10 (p< 0.0001) and EUROHIS-QOL8 (p< 0.0001). In many other aspects of the disease, such as disease duration, levodopa equivalent daily dose, motor symptoms, non-motor symptoms, and autonomy for activities of daily living, an association between the stage and severity was observed, with data indicating a progressive worsening related to disease progression throughout the proposed stages., Conclusion: Staging PD according to the MNCD classification correlated with QoL and disease severity. The MNCD could be a proper tool to monitor the progression of PD.

Published
2023

25. Staging Parkinson's disease according to the MNCD classification correlates with caregiver burden

Author

Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Junta de Andalucía, European Commission, Fundación Alimerka, Sociedad Andaluza de Neurología, Jacques and Gloria Gossweiler Foundation, Fundación Alicia Koplowitz, Fundación Mutua Madrileña, Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., García Díaz, Iago, Íñiguez-Alvarado, María Cristina, Paz, José Manuel, Jesús Maestre, Silvia, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Mendoza, Zebenzui, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Seijo, Manuel, Valero, Caridad, Alonso Redondo, Rubén, Buongiorno, Maria Teresa, Ordás, Carlos, Menéndez-González, Manuel, McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, COPPADIS Study Group, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Junta de Andalucía, European Commission, Fundación Alimerka, Sociedad Andaluza de Neurología, Jacques and Gloria Gossweiler Foundation, Fundación Alicia Koplowitz, Fundación Mutua Madrileña, Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., García Díaz, Iago, Íñiguez-Alvarado, María Cristina, Paz, José Manuel, Jesús Maestre, Silvia, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Mendoza, Zebenzui, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Seijo, Manuel, Valero, Caridad, Alonso Redondo, Rubén, Buongiorno, Maria Teresa, Ordás, Carlos, Menéndez-González, Manuel, McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, and COPPADIS Study Group

Abstract

[Background and objective] Recently, we demonstrated that staging Parkinson's disease (PD) with a novel simple classification called MNCD, based on four axes (motor, non-motor, cognition, and dependency) and five stages, correlated with disease severity and patients’ quality of life. Here, we analyzed the correlation of MNCD staging with PD caregiver's status., [Patients and methods] Data from the baseline visit of PD patients and their principal caregiver recruited from 35 centers in Spain from the COPPADIS cohort from January 2016 to November 2017 were used to apply the MNCD total score (from 0 to 12) and MNCD stages (from 1 to 5) in this cross-sectional analysis. Caregivers completed the Zarit Caregiver Burden Inventory (ZCBI), Caregiver Strain Index (CSI), Beck Depression Inventory-II (BDI-II), PQ-10, and EUROHIS-QOL 8-item index (EUROHIS-QOL8)., [Results] Two hundred and twenty-four PD patients (63 ± 9.6 years old; 61.2% males) and their caregivers (58.5 ± 12.1 years old; 67.9% females) were included. The frequency of MNCD stages was 1, 7.6%; 2, 58.9%; 3, 31.3%; and 4–5, 2.2%. A more advanced MNCD stage was associated with a higher score on the ZCBI (p < .0001) and CSI (p < .0001), and a lower score on the PQ-10 (p = .001), but no significant differences were observed in the BDI-II (p = .310) and EUROHIS-QOL8 (p = .133). Moderate correlations were observed between the MNCD total score and the ZCBI (r = .496; p < .0001), CSI (r = .433; p < .0001), and BDI-II (r = .306; p < .0001) in caregivers., [Conclusion] Staging PD according to the MNCD classification is correlated with caregivers’ strain and burden.

Published
2023

26. Cognitive impairment and dementia in young onset Parkinson’s disease

Author

Fundación Degén, Alpha Bioresearch, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., García Díaz, Iago, Íñiguez-Alvarado, María Cristina, Paz, José Manuel, Jesús Maestre, Silvia, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Mendoza, Zebenzui, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Seijo, Manuel, Valero, Caridad, Alonso Redondo, Rubén, Buongiorno, Maria Teresa, Ordás, Carlos, Menéndez-González, Manuel, McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, COPPADIS Study Group, Fundación Degén, Alpha Bioresearch, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., García Díaz, Iago, Íñiguez-Alvarado, María Cristina, Paz, José Manuel, Jesús Maestre, Silvia, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Mendoza, Zebenzui, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Seijo, Manuel, Valero, Caridad, Alonso Redondo, Rubén, Buongiorno, Maria Teresa, Ordás, Carlos, Menéndez-González, Manuel, McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, and COPPADIS Study Group

Abstract

[Background and objective] Patients with young-onset Parkinson’s disease (YOPD) have a slower progression. Our aim was to analyze the change in cognitive function in YOPD compared to patients with a later onset and controls., [Patients and methods] Patients with Parkinson’s disease (PD) and controls from the COPPADIS cohort were included. Cognitive function was assessed with the Parkinson’s Disease Cognitive Rating Scale (PD-CRS) at baseline (V0), 2-year ± 1 month (V2y), and 4-year ± 3 months follow-up (V4y). Regarding age from symptoms onset, patients were classified as YOPD (< 50 years) or non-YOPD (≥ 50). A score in the PD-CRS < 81 was defined as cognitive impairment (CI): ≤ 64 dementia; 65–80 mild cognitive impairment (MCI)., [Results] One-hundred and twenty-four YOPD (50.7 ± 7.9 years; 66.1% males), 234 non-YOPD (67.8 ± 7.8 years; 59.3% males) patients, and 205 controls (61 ± 8.3 years; 49.5% males) were included. The score on the PD-CRS and its subscore domains was higher at all visits in YOPD compared to non-YOPD patients and to controls (p < 0.0001 in all analysis), but no differences were detected between YOPD patients and controls. Only non-YOPD patients had significant impairment in their cognitive function from V0 to V4y (p < 0.0001). At V4y, the frequency of dementia and MCI was 5% and 10% in YOPD compared to 25.2% and 22.3% in non-YOPD patients (p < 0.0001). A lower score on the Parkinson’s Disease Sleep Scale at baseline was a predictor of CI at V4y in YOPD patients (Adjusted R2 = 0.61; OR = 0.965; p = 0.029)., [Conclusion] Cognitive dysfunction progressed more slowly in YOPD than in non-YOPD patients.

Published
2023

27. Changes in Principal Caregiver Mood Affects the Mood of the Parkinson’s Disease Patient: The Vicious Cycle of Illness

Author

Fundación Degen, Alpha Bioresearch, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., Íñiguez-Alvarado, María Cristina, García Díaz, Iago, Jesús Maestre, Silvia, Buongiorno, Maria Teresa, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Puente, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Menéndez-González, Manuel, Seijo, Manuel, Ruiz Martínez, Javier, Valero, Caridad, Kurtis, Mónica, González Ardura, Jessica, Alonso Redondo, Rubén, Ordás, Carlos, López-Díaz, Luis M., McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, COPPADIS Study Group, Fundación Degen, Alpha Bioresearch, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., Íñiguez-Alvarado, María Cristina, García Díaz, Iago, Jesús Maestre, Silvia, Buongiorno, Maria Teresa, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Puente, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Menéndez-González, Manuel, Seijo, Manuel, Ruiz Martínez, Javier, Valero, Caridad, Kurtis, Mónica, González Ardura, Jessica, Alonso Redondo, Rubén, Ordás, Carlos, López-Díaz, Luis M., McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, and COPPADIS Study Group

Abstract

Background: Although many studies have analyzed what factors contribute to caregiver burden in Parkinson’s disease (PD), there is currently no knowledge about how the status of the caregiver could impact the patient., Objective: The aim of this study was to analyze how the change in the caregiver’s status influences PD patients., Methods: PD patients and their caregivers who were recruited from January/2016 to November/2017 from 35 centers in Spain from the COPPADIS cohort were included in the study (V0). They were evaluated again at 2-year follow-up (V2). Caregivers completed the Zarit Caregiver Burden Inventory (ZCBI), Caregiver Strain Index (CSI), Beck Depression Inventory-II (BDI-II), and EUROHIS-QOL 8-item index (EUROHIS-QOL8) at V0 and V2. Multivariate models were used to analyze the impact of the change from V0 to V2 () on the caregiver’s status over the change in the patient’s status., Results: BDI-II and EUROHIS-QOL8 in the caregiver predicted BDI-II ( = 0.32; p < 0.0001; R2 = 0.71) and EUROHIS-QOL8 ( = 0.39; p < 0.0001; R2 = 0.68) in the patient, respectively. Variables related to the caregiver were not associated with changes in the patient´s health-related QoL (PDQ-39 [39-item Parkinson’s disease Questionnaire]) or autonomy for activities of daily-living (ADLS [Schwab & England Activities of Daily Living Scale])., Conclusion: The change in the caregiver’s mood and global QoL was associated with the change in the patient’s mood and global QoL, respectively, independently of other variables of the disease influencing both patient´s aspects. Based on this finding, it could be of great importance to detect depression in the principal caregiver of a patient and act on it as earlier as possible.

Published
2023

28. Prevalence and Factors Associated with Drooling in Parkinson’s Disease: Results from a Longitudinal Prospective Cohort and Comparison with a Control Group

Author

Fundación Degen, Alpha Bioresearch, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., Íñiguez-Alvarado, María Cristina, Jesús Maestre, Silvia, Buongiorno, Maria Teresa, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Puente, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Blázquez-Estrada, Marta, Seijo, Manuel, Ruiz Martínez, Javier, Valero, Caridad, Kurtis, Mónica, Fábregues-Boixar, Oriol de, González Ardura, Jessica, Alonso Redondo, Rubén, Ordás, Carlos, López-Díaz, Luis M., McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, Study Group COPPADIS, Fundación Degen, Alpha Bioresearch, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Feal Painceiras, María J., Íñiguez-Alvarado, María Cristina, Jesús Maestre, Silvia, Buongiorno, Maria Teresa, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Puente, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Blázquez-Estrada, Marta, Seijo, Manuel, Ruiz Martínez, Javier, Valero, Caridad, Kurtis, Mónica, Fábregues-Boixar, Oriol de, González Ardura, Jessica, Alonso Redondo, Rubén, Ordás, Carlos, López-Díaz, Luis M., McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, and Study Group COPPADIS

Abstract

Introduction. Drooling in Parkinson’s disease (PD) is frequent but often goes underrecognized. Our aim was to examine the prevalence of drooling in a PD cohort and compare it with a control group. Specifcally, we identifed factors associated with drooling and conducted subanalyses in a subgroup of very early PD patients. Patients and Methods. PD patients who were recruited from January 2016 to November 2017 (baseline visit; V0) and evaluated again at a 2-year ± 30-day follow-up (V2) from 35 centers in Spain from the COPPADIS cohort were included in this longitudinal prospective study. Subjects were classifed as with or without drooling according to item 19 of the NMSS (Nonmotor Symptoms Scale) at V0, V1 (1-year ± 15 days), and V2 for patients and at V0 and V2 for controls. Results. Te frequency of drooling in PD patients was 40.1% (277/691) at V0 (2.4% (5/201) in controls; p < 0.0001), 43.7% (264/604) at V1, and 48.2% (242/502) at V2 (3.2% (4/124) in controls; p < 0.0001), with a period prevalence of 63.6% (306/481). Being older (OR = 1.032; p = 0.012), being male (OR = 2.333; p < 0.0001), having greater nonmotor symptom (NMS) burden at the baseline (NMSS total score at V0; OR = 1.020; p < 0.0001), and having a greater increase in the NMS burden from V0 to V2 (change in the NMSS total score from V0 to V2; OR = 1.012; p < 0.0001) were identifed as independent predictors of drooling after the 2-year follow-up. Similar results were observed in the group of patients with ≤2 years since symptom onset, with a cumulative prevalence of 64.6% and a higher score on the UPDRS-III at V0 (OR = 1.121; p = 0.007) as a predictor of drooling at V2. Conclusion. Drooling is frequent in PD patients even at the initial onset of the disease and is associated with a greater motor severity and NMS burden.

Published
2023

29. Staging Parkinson's disease according to the MNCD classification correlates with caregiver burden.

Author

Santos‐García, Diego, de Deus Fonticoba, Teresa, Cores Bartolomé, Carlos, Feal Painceiras, María J., García Díaz, Iago, Alvarado, María Cristina Íñiguez, Paz, Jose Manuel, Jesús, Silvia, Cosgaya, Marina, Caldentey, Juan García, Caballol, Nuria, Legarda, Ines, Hernández Vara, Jorge, Cabo, Iria, López Manzanares, Lydia, González Aramburu, Isabel, Ávila Rivera, Maria A., Gómez Mayordomo, Víctor, Nogueira, Víctor, and Dotor García‐Soto, Julio

Published
2023
Full Text
View/download PDF

30. Prevalence and Factors Associated with Drooling in Parkinson’s Disease: Results from a Longitudinal Prospective Cohort and Comparison with a Control Group

Author

Santos-García, Diego, primary, de Deus Fonticoba, Teresa, additional, Cores Bartolomé, Carlos, additional, Feal Painceiras, Maria J., additional, Íñiguez-Alvarado, Maria Cristina, additional, Jesús, Silvia, additional, Buongiorno, Maria Teresa, additional, Planellas, Lluís, additional, Cosgaya, Marina, additional, García Caldentey, Juan, additional, Caballol, Nuria, additional, Legarda, Ines, additional, Hernández Vara, Jorge, additional, Cabo, Iria, additional, López Manzanares, Lydia, additional, González Aramburu, Isabel, additional, Ávila Rivera, Maria A., additional, Gómez Mayordomo, Víctor, additional, Nogueira, Víctor, additional, Puente, Víctor, additional, Dotor García-Soto, Julio, additional, Borrué, Carmen, additional, Solano Vila, Berta, additional, Álvarez Sauco, María, additional, Vela, Lydia, additional, Escalante, Sonia, additional, Cubo, Esther, additional, Carrillo Padilla, Francisco, additional, Martínez Castrillo, Juan C., additional, Sánchez Alonso, Pilar, additional, Alonso Losada, Maria G., additional, López Ariztegui, Nuria, additional, Gastón, Itziar, additional, Kulisevsky, Jaime, additional, Blázquez Estrada, Marta, additional, Seijo, Manuel, additional, Rúiz Martínez, Javier, additional, Valero, Caridad, additional, Kurtis, Mónica, additional, de Fábregues, Oriol, additional, González Ardura, Jessica, additional, Alonso Redondo, Ruben, additional, Ordás, Carlos, additional, López Díaz, Luis M. L., additional, McAfee, Darrian, additional, Martinez-Martin, Pablo, additional, Mir, Pablo, additional, and COPPADIS, Study Group, additional

Published
2023
Full Text
View/download PDF

31. Prevalence and Factors Associated with Drooling in Parkinson’s Disease: Results from a Longitudinal Prospective Cohort and Comparison with a Control Group

Author

Diego Santos-García, Teresa de Deus Fonticoba, Carlos Cores Bartolomé, Maria J. Feal Painceiras, Maria Cristina Íñiguez-Alvarado, Silvia Jesús, Maria Teresa Buongiorno, Lluís Planellas, Marina Cosgaya, Juan García Caldentey, Nuria Caballol, Ines Legarda, Jorge Hernández Vara, Iria Cabo, Lydia López Manzanares, Isabel González Aramburu, Maria A. Ávila Rivera, Víctor Gómez Mayordomo, Víctor Nogueira, Víctor Puente, Julio Dotor García-Soto, Carmen Borrué, Berta Solano Vila, María Álvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Francisco Carrillo Padilla, Juan C. Martínez Castrillo, Pilar Sánchez Alonso, Maria G. Alonso Losada, Nuria López Ariztegui, Itziar Gastón, Jaime Kulisevsky, Marta Blázquez Estrada, Manuel Seijo, Javier Rúiz Martínez, Caridad Valero, Mónica Kurtis, Oriol de Fábregues, Jessica González Ardura, Ruben Alonso Redondo, Carlos Ordás, Luis M. L. López Díaz, Darrian McAfee, Pablo Martinez-Martin, Pablo Mir, Study Group COPPADIS, Institut Català de la Salut, [Santos-García D, Cores Bartolomé C, Feal Painceiras MJ, Íñiguez-Alvarado MC] CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. [de Deus Fonticoba T] CHUF, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain. [Jesús S] Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Seville, Spain. CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), Madrid, Spain. [Hernández Vara J] CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), Madrid, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [de Fábregues O] Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Psychiatry and Mental health, enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::enfermedades de los ganglios basales::trastornos parkinsonianos::enfermedad de Parkinson [ENFERMEDADES], Article Subject, Neuroscience (miscellaneous), Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Basal Ganglia Diseases::Parkinsonian Disorders::Parkinson Disease [DISEASES], técnicas de investigación::métodos epidemiológicos::recopilación de datos::estadísticas vitales::morbilidad::prevalencia [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], enfermedades estomatognáticas::enfermedades de la boca::enfermedades de las glándulas salivales::sialorrea [ENFERMEDADES], Neurology (clinical), Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Saliva, Parkinson, Malaltia de - Epidemiologia, Stomatognathic Diseases::Mouth Diseases::Salivary Gland Diseases::Sialorrhea [DISEASES]
Abstract

Introduction. Drooling in Parkinson’s disease (PD) is frequent but often goes underrecognized. Our aim was to examine the prevalence of drooling in a PD cohort and compare it with a control group. Specifically, we identified factors associated with drooling and conducted subanalyses in a subgroup of very early PD patients. Patients and Methods. PD patients who were recruited from January 2016 to November 2017 (baseline visit; V0) and evaluated again at a 2-year ± 30-day follow-up (V2) from 35 centers in Spain from the COPPADIS cohort were included in this longitudinal prospective study. Subjects were classified as with or without drooling according to item 19 of the NMSS (Nonmotor Symptoms Scale) at V0, V1 (1-year ± 15 days), and V2 for patients and at V0 and V2 for controls. Results. The frequency of drooling in PD patients was 40.1% (277/691) at V0 (2.4% (5/201) in controls; p p p = 0.012), being male (OR = 2.333; p p p p = 0.007) as a predictor of drooling at V2. Conclusion. Drooling is frequent in PD patients even at the initial onset of the disease and is associated with a greater motor severity and NMS burden.

Published
2023
Full Text
View/download PDF

32. Análisis de prefactibilidad para la creación de una planta procesadora de derivados plásticos que contribuya a la mejora de las capacidades técnicas en el procesamiento del plástico reciclado, en la ciudad de Managua durante el período 2021

Author

Ávila Rivera, Carmen María

Subjects
354.6 Administración Publica, 658.404 Evaluación de proyectos
Abstract

Este trabajo investigativo se realizó con una visión social que contribuya al mejoramiento ambiental, desarrollo económico del país, identificar a los posibles beneficiados con esta planta transformadora de plástico en otros productos y contribuir en darle otro uso a esta materia prima. Por lo que el proyecto tiene como fin mostrar la viabilidad comercial y técnica, además de la rentabilidad que resulta de identificar una oportunidad de reciclaje con la creación de una planta procesadora de derivado plástico, orientada a la producción más limpia. El análisis de pre factibilidad para crear una planta procesadora de derivados plásticos en la ciudad de Managua, se desarrolló con el método de preparación (formulación) y evaluación de proyecto con un enfoque investigativo mixto. En el estudio de pre factibilidad, se realizaron diversos estudios relacionados entre sí entre ellos: (i) identificación del Proyecto, que consiste en realizar un diagnóstico de los problemas que motivan el Proyecto, identificar alternativas de solución; (ii) formulación del Proyecto, donde se analiza la demanda y oferta de productos derivados del plástico; se elaboró a nivel técnico el emplazamiento, tecnología y tamaño capacidad de oferta del Proyecto; fueron determinados sus costos de inversión, gastos de operación y mantenimiento; gastos administrativos y (iii) el proceso de evaluación del Proyecto, en que se determinan los flujos de beneficios y costos socioeconómicos y los indicadores de rentabilidad, asimismo, se construyen escenarios de evaluación, basado en la sensibilidad de las variables críticas, tanto endógenas como exógenas, para la sostenibilidad de la iniciativa de inversión. Palabras claves: Pre factibilidad, plástico reciclado, ciclo de vida del proyecto, proyecto

Published
2022

35. 20604. LA CLASIFICACIÓN MNCD CORRELACIONA MEJOR CON LA CALIDAD DE VIDA Y SITUACIÓN FUNCIONAL EN LOS PACIENTES CON ENFERMEDAD DE PARKINSON QUE EL HOEHN Y YAHR

Author

Gallego González, L., Santos García, D., de Deus Fonticoba, T., Jesús Maestre, S., Cosgaya, M., García Caldentey, J., Caballol Pons, N., Legarda, I., Hernández Vara, J., Cabo, I., López Manzanares, L., González Aramburu, I., Ávila Rivera, M., Gómez Mayordomo, V., Nogueira Fernández, V., García Soto, J., Borrué Fernández, C., Solano Vila, B., Álvarez Sauco, M., Vela, L., Escalante, S., Cubo, E., Mendoza, Z., Pareés, I., Sánchez Alonso, P., Alonso Losada, M., López Ariztegui, N., Gastón, I., Kulisevsky, J., Seijo Martínez, M., Valero Merino, C., Alonso Redondo, R., Ordás, C., Menéndez González, M., Martínez Martín, P., and Mir Rivera, P.

Published
2024
Full Text
View/download PDF

36. Percepción de Internos de Medicina de la Universidad de Antofagasta respecto a la formación académica recibida para enfrentar el ciclo profesional

Author

Torres Belma, Alberto Rodolfo, primary, Álvarez Iguaín, Claudia, additional, Vergara Picón, Lila, additional, Ávila Rivera, Rosa, additional, Rauld Olmos, Nicolás, additional, Jujumaya Fuentes, Camilo, additional, Fernández Gallardo, Juan, additional, and Tapia da Silva, Belén, additional

Published
2022
Full Text
View/download PDF

37. Decreto ejecutivo 813 y su incidencia como causal de cesación en la administración pública ecuatoriana

Author

Ávila Rivera, Eduardo Francisco, Vaca Acosta, Pablo Miguel, Castro Sánchez, Fernando-De-Jesús, Ávila Rivera, Eduardo Francisco, Vaca Acosta, Pablo Miguel, and Castro Sánchez, Fernando-De-Jesús

Abstract

The objective is to analyze the legal consequences of the application of Executive Decree 813 issued on July 12, 2011, in order to determine the effects on the efficiency of the Administrative Management due to the dismissal of public servants, without the existence of an established procedure for their dismissal. Descriptive documentary research with bibliographic design. The figure of purchase of compulsory resignation with compensation, which terminates the functions of public servants from their jobs without there being a voluntary act of resignation from their jobs, implying a violation of labor rights and guarantees established in the Constitution and of the administrative processes framed in the Organic Law of the Public Service., Se tiene por objetivo analizar las consecuencias jurídicas de la aplicación del Decreto Ejecutivo 813 expedido el 12 de julio de 2011, con la finalidad de determinar los efectos en la eficiencia de la Gestión Administrativa por la desvinculación de servidores públicos, sin que exista un procedimiento establecido para su cesación. Investigación de tipo documental descriptiva con diseño bibliográfico. La figura de compra de renuncia obligatoria con indemnización, que cesa en funciones a los servidores públicos de sus puestos de trabajo sin que exista un acto voluntario de renuncia a su puesto de trabajo, suponiendo una violación de derechos y garantías laborales establecidas en la Constitución y de los procesos administrativos enmarcados en la Ley Orgánica del Servicio Público.

Published
2022

38. Parkinson's Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up

Author

Santos-García, Diego, Canfield, Hector, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Naya Ríos, Lucía, García Roca, Lucía, Martínez Miró, Cristina, Jesús Maestre, Silvia, Aguilar, Miquel, Pastor, Pau, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Puente, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Blázquez-Estrada, Marta, Seijo, Manuel, Ruiz Martínez, Javier, Valero, Caridad, Kurtis, Mónica, Fábregues-Boixar, Oriol de, González Ardura, Jessica, Alonso Redondo, Rubén, Ordás, Carlos, López-Díaz, Luis M., McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, COPPADIS Study Group, Santos-García, Diego, Canfield, Hector, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Naya Ríos, Lucía, García Roca, Lucía, Martínez Miró, Cristina, Jesús Maestre, Silvia, Aguilar, Miquel, Pastor, Pau, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Inés, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Puente, Víctor, Dotor, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Blázquez-Estrada, Marta, Seijo, Manuel, Ruiz Martínez, Javier, Valero, Caridad, Kurtis, Mónica, Fábregues-Boixar, Oriol de, González Ardura, Jessica, Alonso Redondo, Rubén, Ordás, Carlos, López-Díaz, Luis M., McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, and COPPADIS Study Group

Abstract

[Background] Motor phenotype (MP) can be associated with a different prognosis in Parkinson's disease (PD), but it is not fixed and can change over time., [Objective] Our aim was to analyze how the MP changed over time and to identify factors associated with the changes in PD patients from a multicenter Spanish PD cohort., [Methods] PD patients who were recruited from January-2016 to November-2017 (baseline visit; V0) and evaluated again at a 2-year±30 days follow-up (V2) from 35 centers of Spain from the COPPADIS cohort, were included in this study.MP was calculated at both visits based on Jankovic classification in TD (tremor dominant), IND (indeterminate), or PIGD (postural instability and gait difficulty). Sociodemographic and clinical data were collected, including serum biomarkers., [Results] Five hundred eleven patients (62.57±8.59 years old; 59.2%males) were included in the study. At V0, MP was: 47.4%(242/511) TD; 36.6%(187/511) PIGD; 16%(82/511) IND. Up to 38%(194/511) of the patients changed their phenotype from V0 to V2, being the most frequent from TD to IND (8.4%) and from TD to PIGD (6.7%). A worse cognitive status (OR = 0.966) and less autonomy for activities of daily living (OR = 0.937) at V0 and a greater increase in the globalNMS burden (OR = 1.011) from V0 to V2 were associated with changing from TD to another phenotype after 2-year follow-up., [Conclusion] The MP in PD can change over time. With disease progression, the percentage of cases with non-tremoric MP increases. PD patients who changed from TD to postural instability and gait difficulty increased NMS burden significantly.

Published
2022

39. Speech pause distribution as an early marker for Alzheimer’s disease

Author

Universitat Politècnica de Catalunya. Institut de Ciències de l'Educació, Universitat Politècnica de Catalunya. LARCA - Laboratori d'Algorísmia Relacional, Complexitat i Aprenentatge, Pastoriza-Domínguez, Patricia, González Torre, Ivan, Diéguez-Vide, Faustino, Gómez Ruiz, María Isabel, Geladó Muñoz, Sandra, Bello-López, Joan, Ávila-Rivera, Asunción, Matías-Guiu, Jordi, Pytel Córdoba, Vanesa, Hernández Fernández, Antonio, Universitat Politècnica de Catalunya. Institut de Ciències de l'Educació, Universitat Politècnica de Catalunya. LARCA - Laboratori d'Algorísmia Relacional, Complexitat i Aprenentatge, Pastoriza-Domínguez, Patricia, González Torre, Ivan, Diéguez-Vide, Faustino, Gómez Ruiz, María Isabel, Geladó Muñoz, Sandra, Bello-López, Joan, Ávila-Rivera, Asunción, Matías-Guiu, Jordi, Pytel Córdoba, Vanesa, and Hernández Fernández, Antonio

Abstract

Background: Pause duration analysis is a common feature in the study of discourse in Alzheimer’s disease (AD) since this patient group has shown a consistent trend for longer pauses in comparison to healthy controls. This speech feature may also be helpful for early detection; however, studies involving patients at the pre-clinical, high-risk phase of amnestic mild cognitive impairment (aMCI) have yielded varying results. Objective: To characterize the probability density distribution of speech pause durations in 26 patients with AD, 57 amnestic multi-domain amnestic MCI patients (29 with memory encoding deficits, a-mdMCI-E, and 28 with retrieval impairment only, a-mdMCI-R) and 29 healthy controls (HC) in order assess whether there are significant differences between them. To explore the potential differences in pause production between patients with a-mdMCI-E and a-mdMCI-R, as the former are considered to be at higher risk of progressing to dementia. Methods: The 112 picture-based oral narratives obtained were manually transcribed and annotated for the automatic extraction and analysis of pause durations. Different probability distributions were tested for the fitting of pause durations while truncating shorter ranges. Recent findings in the field of Statistics were considered in order to avoid the inherent methodological uncertainty that this type of analysis entails by addressing the question of temporal thresholding and its potential repercussions on inter-annotator reliability in manual transcriptions. Results: A lognormal distribution (LND) explained the distribution of pause duration for all groups. Its fitted parameters (, ) followed a gradation from the group with shorter durations and a higher tendency to produce short pauses (HC) to the group with longer pause durations and a considerably higher tendency to produce long pauses with greater variance (AD). Importantly, a-mdMCI-E produced significantly longer pauses and with greater variability than their a, This work is supported through a PhD grant awarded to P.P-D. by the banking Foundation ‘‘La Caixa’’ (ID 100010434, code: LCF/BQ/ES15/10360020). F.D-V. was supported by a grant awarded to project no. PID2019-107042GB-I00 (Ministerio de Ciencia e Innovación). A.H-F. and I.G.T. were supported by the grant no. TIN2017- 89244-R (MACDA) (Ministerio de Economia, Industria y Competitivi- dad, Gobierno de España) and the project PRO2020-S03 (RCO03080 Lingüística Quantitativa) of l’Institut d’Estudis Catalans., Peer Reviewed, Objectius de Desenvolupament Sostenible::3 - Salut i Benestar, Postprint (published version)

Published
2022

40. Predictors of the change in burden, strain, mood, and quality of life among caregivers of Parkinson's disease patients

Author

Santos-García, Diego, Deus Fonticoba, T. de, Cores Bartolomé, Carlos, Íñiguez Alvarado, María Cristina, Feal Panceiras, M. J., Suárez Castro, Ester, Canfield, Héctor, Martínez Miró, Cristina, Jesús, Silvia, Aguilar, Miquel, Pastor, Pau, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Ines, Hernández-Vara, Jorge, Cabo, Iria, López-Manzanares, Lydia, González-Aramburu, Isabel, Ávila-Rivera, María A., Gómez Mayordomo, Víctor, Nogueira, Víctor, Puente, Víctor, Dotor García-Soto, Julio, Borrué, Carmen, Solano Vila, Berta, Álvarez-Sauco, María, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, J. C., Sánchez Alonso, Pilar, Alonso Losada, María G., López-Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Blázquez-Estrada, Marta, Seijo, Manuel, Ruiz Martínez, Javier, Valero, Caridad, Kurtis, Mónica, Fábregues-Boixar, Oriol de, González Ardura, Jessica, Alonso Redondo, Rubén, Ordás, Carlos, López-Díaz, Luis M., McAfee, Darrian, Martínez-Martín, Pablo, Mir, Pablo, COPPADIS Study Group, AbbVie Pharmaceuticals, UCB Pharma, Lundbeck, Krka Farmacéutica, Zambon, BIAL Foundation, Italfarmaco, Teva Pharmaceutical Industries, Merz Pharma, Instituto de Salud Carlos III, Junta de Andalucía, Qualigen, Nutricia Foundation, Sanofi, Merck & Co, Allergan Foundation, Roche, Novartis, International Parkinson and Movement Disorder Society, Ipsen, Exeltis, Fundació La Marató de TV3, Daiichi-Sankyo, Sociedad Española de Neurología, Esteve, Psyma Ibérica, Abbott Laboratories, European Commission, Jacques and Gloria Gossweiler Foundation, Fundación Alicia Koplowitz, Fundación Mutua Madrileña, and Santos-García, Diego

Subjects
Psychiatry and Mental health, strain, mood, Parkinson's disease, Mood, Burden, Geriatrics and Gerontology, Caregiver, caregiver, Strain, burden
Abstract

[Background and Objective] Caregiver burden in Parkinson's disease (PD) has been studied in many cross-sectional studies but poorly in longitudinal ones. The aim of the present study was to analyze the change in burden, strain, mood, and quality of life (QoL) after a 2-year follow-up in a cohort of caregivers of patients with PD and also to identify predictors of these changes., [Patients and Methods] PD patients and their caregivers who were recruited from January/2016 to November/2017 from 35 centers of Spain from the COPPADIS cohort were included in the study. They were evaluated again at 2-year follow-up. Caregivers completed the Zarit Caregiver Burden Inventory (ZCBI), Caregiver Strain Index (CSI), Beck Depression Inventory-II (BDI-II), and EUROHIS-QOL 8-item index (EUROHIS-QOL8) at baseline (V0) and at 2-year follow-up (V2). General linear model repeated measure and lineal regression models were applied., [Results] Significant changes, indicating an impairment, were detected on the total score of the ZCBI (p < 0.0001), CSI (p < 0.0001), BDI-II (p = 0.024), and EUROHIS-QOL8 (p = 0.002) in 192 PD caregivers (58.82 ± 11.71 years old; 69.3% were females). Mood impairment (BDI-II; β = 0.652; p < 0.0001) in patients from V0 to V2 was the strongest factor associated with caregiver's mood impairment after the 2-year follow-up. Caregiver's mood impairment was the strongest factor associated with an increase from V0 to V2 on the total score of the ZCBI (β = 0.416; p < 0.0001), CSI (β = 0.277; p = 0.001), and EUROHIS-QOL (β = 0.397; p = 0.002)., [Conclusion] Burden, strain, mood, and QoL were impaired in caregivers of PD patients after a 2-year follow-up. Mood changes in both the patient and the caregiver are key aspects related to caregiver burden increase., Santos García D. has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, Italfarmaco, and Teva. De Deus Fonticoba T.: None. Cores Bartolomé C. has received honoraria for educational presentations and advice service by Lundbeck and UCB Pharma. Íñiguez Alvarado MC: None. Feal Painceiras M. J.: None. Martínez Miró C.: None. Suárez Castro E.: None. Canfield H.: None. Jesús S. has received honoraria from AbbVie, Bial, Merz, UCB, and Zambon and holds the competitive contract “Juan Rodés” supported by the Instituto de Salud Carlos III. She has received grants from the Spanish Ministry of Economy and Competitiveness (PI18/01898) and the Consejería de Salud de la Junta de Andalucía (PI-0459-2018). Aguilar M.: UCB and Schwabe with assistance to a Congress; Nutricia with assistance to a Congress and payment of lecture. Pastor P.: None. Planellas LL.: None. Cosgaya M.: None. García Caldentey J. has received honoraria for educational presentations and advice service by Qualigen, Nutricia, Abbvie, Italfarmaco, UCB Pharma, Lundbeck, Zambon, Bial, and Teva. Caballol N. has received honoraria from Bial, Italfármaco, Qualigen, Zambon, UCB, Teva and KRKA and sponsorship from Zambon, TEVA and Abbvie for attending medical conferences. Legarda I. has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Zambon, Bial, and Teva. Hernández Vara J. has received travel bursaries and educational grants from Abbvie and has received honoraria for educational presentations from Abbvie, Teva, Bial, Zambon, Italfarmaco, and Sanofi-Genzyme. Cabo I. has received honoraria for educational presentations and advice service by Abbvie, Zambon, and Bial. López Manzanares L.: Compensated advisory services, consulting, research grant support, or speaker honoraria: AbbVie, Acorda, Bial, Intec Pharma, Italfarmaco, Pfizer, Roche, Teva, UCB, and Zambon. González Aramburu I.: None. Ávila Rivera MA. has received honoraria from Zambon, UCB Pharma, Qualigen, Bial, and Teva, and sponsorship from Zambon and Teva for attending conferences. Gómez Mayordomo V.: None. Nogueira V.: None. Puente V. has served as consultant for Abbvie and Zambon; has received grant/research from Abbvie. Dotor García-Soto J.: Compensated advisory services, consulting, research grant support, or speaker honoraria: Merck, Sanofi-Genzyme, Allergan, Biogen, Roche, UCB and Novartis. Borrué C.: None. Solano Vila B. has received honoraria for educational presentations and advice service by UCB, Zambon, Teva, Abbvie, Bial. Álvarez Sauco M. has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Zambon, Bial, and Teva. Vela L. has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, and Teva. Escalante S. has received honoraria for educational presentations and advice service by Abbvie, Zambon, and Bial. Cubo E.: Travel grants: Abbvie, Allergan, Boston; Lecturing honoraria: Abbvie, International Parkinson's disease Movement Disorder Society. Carrillo Padilla F. has received honoraria from Zambon (SEN Congress assistance). Martínez Castrillo JC. has received research support from Lundbeck, Italfarmaco, Allergan, Zambon, Merz, and Abbvie. He has received speaking honoraria from AbbVie, Bial, Italfarmaco, Lundbeck, Krka, TEVA, UCB, Zambon, Allergan, Ipsen, and Merz. Sánchez Alonso P. has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, and Teva. Alonso Losada M. G. has received honoraria for educational presentations and advice service by Zambon and Bial. López Ariztegui N. has received honoraria for educational presentations and advice service by Abbvie, Italfarmaco, Zambon, and Bial. Gastón I. has received research support from Abbvie and Zambon and has served as a consultant for Abbvie, Exelts, and Zambon. Kulisevsky J.: (1) Consulting fees: Roche, Zambon; (2) Stock/allotment: No; (3) Patent royalties/licensing fees: No; (4) Honoraria (e.g. lecture fees): Zambon, Teva, Bial, UCB; (5) Fees for promotional materials: No; (6) Research funding: Roche, Zambon, Ciberned; Instituto de Salud Carlos III; FundacióLa Maratóde TV3; (7) Scholarship from corporation: No; (8) Corporate laboratory funding: No; (9) Others (e.g., trips, travel, or gifts): No. Blázquez Estrada M. has received honoraria for educational presentations and advice service by Abbvie, Abbott, UCB Pharma, Allergan, Zambon, Bial, and Qualigen. Seijo M. has received honoraria for educational services from KRKA, UCB, Zambon, Bial; travel grants from Daiichi and Roche. Ruiz Martínez J. has received honoraria for educational presentations, attending medical conferences, and advice service by Abbvie, UCB Pharma, Zambon, Italfarmaco, Bial, and Teva. Valero C. has received honoraria for educational services from Zambon, Abbvie and UCB. Kurtis M. has received honoraria from Bial, the Spanish Neurology Society, and the International and Movement Disorders Society. de Fábregues O. has received honoraria for educational presentations and advice service by Bial, Zambon, Abbvie, KRKA, and Teva. González Ardura J. has received honoraria for speking from italofarma, Krka, Genzyme, UCB, Esteve, Psyma iberica marketing research SL and Ferrer, course grant from Teva and travel grant from Merck. Alonso Redondo R.: None. Ordás C.: None. López Díaz L. M. has received honoraria from UCB, Lundbeck, and KRKA. McAfee D.: None. Martínez-Martin P. has received honoraria from National School of Public Health (ISCIII), Editorial Viguera and Takeda Pharmaceuticals for lecturing in courses, and from the International Parkinson and Movement Disorder Society (MDS) for management of the Program on Rating Scales. Mir P. has received honoraria from AbbVie, Abbott, Allergan, Bial, Merz, UCB, and Zambon and have received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Subdirección General de Evaluación y Fomento de la Investigación) and by Fondo Europeo de Desarrollo Regional (FEDER), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [ PI-0437-2012, PI-0471-2013], the Sociedad Andaluza de Neurología, the Jacques and Gloria Gossweiler Foundation, the Fundación Alicia Koplowitz, the Fundación Mutua Madrileña.

Published
2022

41. Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group

Author

Marina Cosgaya, Jose M. Paz González, Esther Cubo, Maria G. Alonso Losada, Nuria López Ariztegui, Isabel González Aramburu, Carmen Borrué, Lydia López Manzanares, Jaime Kulisevsky, Iria Cabo, Julio Dotor García-Soto, Pau Pastor, Carlos Cores Bartolomé, Nuria Caballol, Jessica González Ardura, Lucía García Roca, Berta Solano Vila, Luis M. López Díaz L, Víctor Puente, Pablo Martinez-Martin, Juan García Caldentey, Javier Rúiz Martínez, Lydia Vela, Cristina Martínez Miró, Itziar Gastón, Lucía Naya Ríos, Francisco Carrillo Padilla, Ruben Alonso Redondo, Darrian McAfee, Juan C. Martínez Castrillo, Ines Legarda, Silvia Jesús, Carlos Ordás, Víctor Nogueira, Marta Blázquez Estrada, Oriol de Fábregues, Miquel Aguilar, Hector Canfield, Manuel Seijo, Teresa de Deus Fonticoba, Jorge Hernández Vara, Maria A. Ávila Rivera, Pablo Mir, Pilar Sánchez Alonso, Diego Santos García, Lluis Planellas, Caridad Valero, Monica M. Kurtis, Víctor Gómez Mayordomo, Sonia Escalante, and María Álvarez Sauco

Subjects
medicine.medical_specialty, impairment, Constipation, Parkinson's disease, Non-motor symptoms, Disease, Cellular and Molecular Neuroscience, Cognition, Rating scale, Internal medicine, Cognitive Changes, Medicine, Humans, Cognitive Dysfunction, Cognitive decline, business.industry, Parkinson Disease, constipation, medicine.disease, Control Groups, non-motor symptoms, Impairment, Cohort, Parkinson’s disease, Neurology (clinical), medicine.symptom, business, Follow-Up Studies
Abstract

[Background] Constipation has been linked to cognitive impairment development in Parkinson’s disease (PD). Objective:Our aim was to analyze cognitive changes observed in PD patients and controls from a Spanish cohort with regards to the presence or not of constipation. Methods:PD patients and controls recruited from 35 centers of Spain from the COPPADIS cohort from January 2016 to November 2017 were followed-up during 2 years. The change in cognitive status from baseline (V0) to 2-year follow-up was assessed with the PD-CRS (Parkinson’s Disease Cognitive Rating Scale). Subjects with a score ≥1 on item 21 of the NMSS (Non-Motor Symptoms Scale) at baseline (V0) were considered as “with constipation”. Regression analyses were applied for determining the contribution of constipation in cognitive changes., [Results] At V0, 39.7% (198/499) of PD patients presented constipation compared to 11.4% of controls (14/123) (p, [Conclusion] Constipation is associated with cognitive decline in PD patients but not in controls.

Published
2022

42. Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group

Author

Santos García D, García Roca L, de Deus Fonticoba T, Cores Bartolomé C, Naya Ríos L, Canfield H, Paz González JM, Martínez Miró C, Jesús S, Aguilar M, Pastor P, Planellas L, Cosgaya M, García Caldentey J, Caballol N, Legarda I, Hernández Vara J, Cabo I, López Manzanares L, González Aramburu I, Ávila Rivera MA, Gómez Mayordomo V, Nogueira V, Puente V, Dotor García-Soto J, Borrué C, Solano Vila B, Álvarez Sauco M, Vela L, Escalante S, Cubo E, Carrillo Padilla F, Martínez Castrillo JC, Sánchez Alonso P, Alonso Losada MG, López Ariztegui N, Gastón I, Kulisevsky J, Blázquez Estrada M, Seijo M, Rúiz Martínez J, Valero C, Kurtis M, de Fábregues O, González Ardura J, Alonso Redondo R, Ordás C, López Díaz L LM, McAfee D, Martinez-Martin P, Mir P, and COPPADIS Study Group

Subjects
impairment, Cognition, Parkinson's disease, constipation, non-motor symptoms
Abstract

Background: Constipation has been linked to cognitive impairment development in Parkinson's disease (PD). Objective: Our aim was to analyze cognitive changes observed in PD patients and controls from a Spanish cohort with regards to the presence or not of constipation. Methods: PD patients and controls recruited from 35 centers of Spain from the COPPADIS cohort from January 2016 to November 2017 were followed-up during 2 years. The change in cognitive status from baseline (V0) to 2-year follow-up was assessed with the PD-CRS (Parkinson's Disease Cognitive Rating Scale). Subjects with a score >= 1 on item 21 of the NMSS (Non-Motor Symptoms Scale) at baseline (V0) were considered as "with constipation". Regression analyses were applied for determining the contribution of constipation in cognitive changes. Results: At V0, 39.7% (198/499) of PD patients presented constipation compared to 11.4% of controls (14/123) (p < 0.0001). No change was observed in cognitive status (PD-CRS total score) neither in controls without constipation (from 100.24 +/- 13.72 to 100.27 +/- 13.68; p = 0.971) and with constipation (from 94.71 +/- 10.96 to 93.93 +/- 13.03; p = 0.615). The PD-CRS total score decreased significantly in PD patients with constipation (from 89.14 +/- 15.36 to 85.97 +/- 18.09; p

Published
2022

43. Suicidal ideation among people with Parkinson's disease and comparison with a control group.

Author

Santos‐García, Diego, de Deus Fonticoba, Teresa, Cores Bartolomé, Carlos, Feal Panceiras, Maria J., García Díaz, Iago, Íñiguez Alvarado, Maria Cristina, Jesús, Silvia, Teresa Boungiorno, Maria, Planellas, Lluís, Cosgaya, Marina, Caldentey, Juan García, Caballol, Nuria, Legarda, Ines, Hernández Vara, Jorge, Cabo, Iria, López Manzanares, Lydia, González Aramburu, Isabel, Ávila Rivera, Maria A., Gómez Mayordomo, Víctor, and Nogueira, Víctor

Subjects
DRUG therapy for Parkinson's disease, SUICIDE prevention, SUICIDAL ideation, RESEARCH funding, QUESTIONNAIRES, PARKINSON'S disease, DESCRIPTIVE statistics, LONGITUDINAL method, ODDS ratio, MEDICAL appointments, QUALITY of life, PSYCHOLOGICAL tests, PATIENT aftercare, REGRESSION analysis, MENTAL depression, DISEASE complications
Abstract

Background Detection of suicidal ideation (SI) is key for trying to prevent suicide. The aim of this study was to analyze the frequency of SI and related factors in Spanish people with Parkinson's Disease (PwPD) and to compare them with a control group. Methods PD patients and controls recruited from the Spanish cohort COPPADIS from January 2016 to November 2017 were included. Two visits were conducted: V0 (baseline); V2 (2-year ± 1 month follow-up). SI was defined as a score ≥1 on item nine of the Beck Depression Inventory-II (BDI-II). Regression analyses were conducted to identify factors related to SI. Results At baseline, 693 PwPD (60.2% males; 62.59 ± 8.91 years old) and 207 controls (49.8% males; 60.99 ± 8.32 years old) were included. No differences between PwPD and controls were detected in SI frequency at either V0 (5.1% [35/693] vs. 4.3% [9/207]; p = 0.421) or at V2 (5.1% [26/508] vs. 4.8% [6/125]; p = 0.549). Major depression (MD) and a worse quality of life were associated with SI at both visits in PwPD: V0 (MD, OR = 5.63; p = 0.003; PDQ-39, OR = 1.06; p = 0.021); V2 (MD, OR = 4.75; p = 0.027; EUROHIS-QOL8, OR = 0.22; p = 0.006). A greater increase in the BDI-II total score from V0 to V2 was the only factor predicting SI at V2 (OR = 1.21; p = 0.002) along with an increase in the total number of non-antiparkinsonian drugs (OR = 1.39; p = 0.041). Conclusion The frequency of SI (5%) in PwPD was similar to in controls. Depression, a worse quality of life, and a greater comorbidity were related to SI. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Staging Parkinson's Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life.

Author

Santos-García, Diego, de Deus Fonticoba, Teresa, Cores Bartolomé, Carlos, Feal Painceiras, Maria J., Íñiguez-Alvarado, Maria Cristina, García Díaz, Iago, Jesús, Silvia, Buongiorno, Maria Teresa, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Ines, Hernández Vara, Jorge, Cabo, Iria, López Manzanares, Lydia, González Aramburu, Isabel, Ávila Rivera, Maria A., Gómez Mayordomo, Víctor, and Nogueira, Víctor

Subjects
PARKINSON'S disease, NOSOLOGY, QUALITY of life, MOVEMENT disorders, ACTIVITIES of daily living, DISEASE duration
Abstract

Background: Recently, a novel simple classification called MNCD, based on 4 axes (Motor; Non-motor; Cognition; Dependency) and 5 stages, has been proposed to classify Parkinson's disease (PD). Objective: Our aim was to apply the MNCD classification in a cohort of PD patients for the first time and also to analyze the correlation with quality of life (QoL) and disease severity. Methods: Data from the baseline visit of PD patients recruited from 35 centers in Spain from the COPPADIS cohort fromJanuary 2016 to November 2017 were used to apply the MNCD classification. Three instruments were used to assess QoL:1) the 39-item Parkinson's disease Questionnaire [PDQ-39]); PQ-10; the EUROHIS-QOL 8-item index (EUROHIS-QOL8). Results: Four hundred and thirty-nine PD patients (62.05±7.84 years old; 59% males) were included. MNCD stage was:stage 1, 8.4% (N = 37); stage 2, 62% (N = 272); stage 3, 28.2% (N = 124); stage 4-5, 1.4% (N = 6). A more advancedMNCD stage was associated with a higher score on the PDQ39SI (p < 0.0001) and a lower score on the PQ-10 (p< 0.0001) and EUROHIS-QOL8 (p< 0.0001). In many other aspects of the disease, such as disease duration, levodopa equivalent daily dose, motor symptoms, non-motor symptoms, and autonomy for activities of daily living, an association between the stage and severity was observed, with data indicating a progressive worsening related to disease progression throughout the proposed stages. Conclusion: Staging PD according to the MNCD classification correlated with QoL and disease severity. The MNCD could be a proper tool to monitor the progression of PD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Changes in Principal Caregiver Mood Affects the Mood of the Parkinson's Disease Patient: The Vicious Cycle of Illness.

Author

Santos-García, Diego, de Deus Fonticoba, Teresa, Cores Bartolomé, Carlos, Feal Painceiras, Maria J., Íñiguez-Alvarado, Maria Cristina, García Díaz, Iago, Jesús, Silvia, Buongiorno, Maria Teresa, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Ines, Hernández Vara, Jorge, Cabo, Iria, López Manzanares, Lydia, González Aramburu, Isabel, Ávila Rivera, Maria A., Gómez Mayordomo, Víctor, and Nogueira, Víctor

Subjects
PARKINSON'S disease, CAREGIVERS, SERVICES for caregivers, APATHY, NEUROLEPTIC malignant syndrome, BURDEN of care, ALZHEIMER'S disease, PEARSON correlation (Statistics), MOVEMENT disorders
Abstract

The change in caregiver's mood influences the change in patient's mood ( BDI-II; in bright green) whereas the change in caregiver's global QoL is associated to the change in patient's global QoL ( EUROHIS-QOL8; in bright yellow). Keywords: Caregiver; longitudinal; mood; Parkinson's disease; quality of life EN Caregiver longitudinal mood Parkinson's disease quality of life 219 231 13 04/04/23 20230401 NES 230401 INTRODUCTION Parkinson's disease (PD) is a progressive neurodegenerative disorder causing motor and non-motor symptoms (NMS) that result in loss of patient autonomy for activities of daily-living (ADL) and quality of life (QoL) [[1]]. PD patient assessment In PD subjects, information on sociodemographic aspects, factors related to PD, comorbidity, and treatment was collected at baseline (visit V0) and at 2 years±1 month (visit V2). [Extracted from the article]

Published
2023
Full Text
View/download PDF

46. Speech pause distribution as an early marker for Alzheimer’s disease

Author

Pastoriza-Domínguez, Patricia, primary, Torre, Iván G., additional, Diéguez-Vide, Faustino, additional, Gómez-Ruiz, Isabel, additional, Geladó, Sandra, additional, Bello-López, Joan, additional, Ávila-Rivera, Asunción, additional, Matías-Guiu, Jordi A., additional, Pytel, Vanesa, additional, and Hernández-Fernández, Antoni, additional

Published
2022
Full Text
View/download PDF

47. Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up

Author

Santos García, Diego, primary, Naya Ríos, Lucía, additional, de Deus Fonticoba, Teresa, additional, Cores Bartolomé, Carlos, additional, García Roca, Lucía, additional, Feal Painceiras, Maria, additional, Martínez Miró, Cristina, additional, Canfield, Hector, additional, Jesús, Silvia, additional, Aguilar, Miquel, additional, Pastor, Pau, additional, Cosgaya, Marina, additional, García Caldentey, Juan, additional, Caballol, Nuria, additional, Legarda, Inés, additional, Hernández Vara, Jorge, additional, Cabo, Iria, additional, López Manzanares, Lydia, additional, González Aramburu, Isabel, additional, Ávila Rivera, María A., additional, Gómez Mayordomo, Víctor, additional, Nogueira, Víctor, additional, Puente, Víctor, additional, Dotor, Julio, additional, Borrué, Carmen, additional, Solano Vila, Berta, additional, Álvarez Sauco, María, additional, Vela, Lydia, additional, Escalante, Sonia, additional, Cubo, Esther, additional, Carrillo Padilla, Francisco, additional, Martínez Castrillo, Juan C., additional, Sánchez Alonso, Pilar, additional, Alonso Losada, Maria G., additional, López Ariztegui, Nuria, additional, Gastón, Itziar, additional, Kulisevsky, Jaime, additional, Blázquez Estrada, Marta, additional, Seijo, Manuel, additional, Rúiz Martínez, Javier, additional, Valero, Caridad, additional, Kurtis, Mónica, additional, de Fábregues, Oriol, additional, González Ardura, Jessica, additional, Alonso Redondo, Ruben, additional, Ordás, Carlos, additional, López Díaz, Luis M., additional, McAfee, Darrian, additional, Martinez-Martin, Pablo, additional, and Mir, Pablo, additional

Published
2021
Full Text
View/download PDF

48. <scp>COPPADIS</scp> ‐2015 ( <scp>CO</scp> hort of Patients with PArkinson's <scp>DI</scp> sease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation

Author

J.C. Martínez Castrillo, Víctor Puente, J Ruíz Martínez, Esther Cubo, Lluís Planellas, B Solano Vila, Nuria Caballol, J García Caldentey, M Seijo, I González Aramburu, P Sánchez Alonso, O de Fábregues-Boixar, I. Legarda, Pablo Martinez-Martin, C Prieto Jurczynska, Miquel Aguilar, D Santos Garcia, Jaume Kulisevsky, J Hernández Vara, I Gastón, J González Ardura, M J Catalán, M Álvarez Sauco, Iria Cabo, Silvia Jesús, L.M. López Díaz, M Menendez Gonzalez, N López Ariztegui, M G Alonso Losada, C Valero, L. López Manzanares, F Carrillo Padilla, Monica M. Kurtis, S Escalante, M A Ávila Rivera, C Borrué, Lydia Vela, P. Mir, and J M García Moreno

Subjects
medicine.medical_specialty, Parkinson's disease, Impulse control disorder, business.industry, Disease, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Neurology, Quality of life, Internal medicine, Cohort, medicine, Observational study, 030212 general & internal medicine, Neurology (clinical), Prospective cohort study, business, 030217 neurology & neurosurgery, Depression (differential diagnoses)
Abstract

Background and purpose In Parkinson's disease (PD), the course of the disorder is highly variable between patients. Well-designed, prospective studies for identifying PD progression biomarkers are necessary. Our aim was to show the results of baseline evaluations of an ongoing global PD project, COPPADIS-2015 (Cohort of Patients with PArkinson's DIsease in Spain, 2015). Methods This was an observational, descriptive, nationwide study (Spain). The recruitment period ended in October 2017. Baseline evaluation included more than 15 validated scales and complementary studies in a subgroup of participants. Results In total, 1174 subjects from 35 centres were considered valid for baseline analysis: 694 patients (62.6 ± 8.9 years old, 60.3% males), 273 caregivers (58.5 ± 11.9 years old, 31.8% males) and 207 controls (61 ± 8.3 years old, 49.5% males). The mean disease duration was 5.5 ± 4.4 years. Hoehn and Yahr stage was 1 or 2 in 90.7% of the patients whilst 33.9% and 18.1% of them presented motor fluctuations and dyskinesias, respectively. The mean Non-Motor Symptoms Scale total score was 45.4 ± 38.1, and 30.4% of the patients presented cognitive impairment, 16.1% major depression, 12.7% impulse control disorder, 7.2% compulsive behaviour, 57.2% pain and 13.2% falls. Compared to the control group, PD patients presented a significantly higher burden of non-motor symptoms and a worse quality of life. More than 300 subjects conducted complementary studies (serum biomarkers, genetic and neuroimaging). Conclusions Parkinson's disease is a complex disorder and different non-motor symptoms are frequently present and are more prevalent than in controls. In real clinical practice it is important to ask for them.

Published
2019
Full Text
View/download PDF

49. Decreto ejecutivo 813 y su incidencia como causal de cesación en la administración pública ecuatoriana

Author

Eduardo Francisco Ávila-Rivera, Pablo Miguel Vaca-Acosta, and Fernando-De-Jesús Castro-Sánchez

Subjects
General Earth and Planetary Sciences, General Environmental Science
Abstract

Se tiene por objetivo analizar las consecuencias jurídicas de la aplicación del Decreto Ejecutivo 813 expedido el 12 de julio de 2011, con la finalidad de determinar los efectos en la eficiencia de la Gestión Administrativa por la desvinculación de servidores públicos, sin que exista un procedimiento establecido para su cesación. Investigación de tipo documental descriptiva con diseño bibliográfico. La figura de compra de renuncia obligatoria con indemnización, que cesa en funciones a los servidores públicos de sus puestos de trabajo sin que exista un acto voluntario de renuncia a su puesto de trabajo, suponiendo una violación de derechos y garantías laborales establecidas en la Constitución y de los procesos administrativos enmarcados en la Ley Orgánica del Servicio Público.

Published
2022
Full Text
View/download PDF

50. Sex Differences in Motor and Non-Motor Symptoms among Spanish Patients with Parkinson's Disease.

Author

Santos-García, Diego, Laguna, Ariadna, Hernández-Vara, Jorge, de Deus Fonticoba, Teresa, Cores Bartolomé, Carlos, Feal Painceiras, Maria J., Íñiguez-Alvarado, Maria Cristina, García Díaz, Iago, Jesús, Silvia, Boungiorno, Maria Teresa, Planellas, Lluís, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Ines, Cabo, Iria, López Manzanares, Lydia, González Aramburu, Isabel, Ávila Rivera, Maria A., and Gómez Mayordomo, Víctor

Subjects
HYPERSEXUALITY, PARKINSON'S disease, NEUROLEPTIC malignant syndrome, MOVEMENT disorders, FATIGUE (Physiology), AGE groups, SYMPTOMS, ACTIVITIES of daily living
Abstract

Background and objective: Sex plays a role in Parkinson's disease (PD) mechanisms. We analyzed sex difference manifestations among Spanish patients with PD. Patients and Methods: PD patients who were recruited from the Spanish cohort COPPADIS from January 2016 to November 2017 were included. A cross-sectional and a two-year follow-up analysis were conducted. Univariate analyses and general linear model repeated measure were used. Results: At baseline, data from 681 PD patients (mean age 62.54 ± 8.93) fit the criteria for analysis. Of them, 410 (60.2%) were males and 271 (39.8%) females. There were no differences between the groups in mean age (62.36 ± 8.73 vs. 62.8 ± 9.24; p = 0.297) or in the time from symptoms onset (5.66 ± 4.65 vs. 5.21 ± 4.11; p = 0.259). Symptoms such as depression (p < 0.0001), fatigue (p < 0.0001), and pain (p < 0.00001) were more frequent and/or severe in females, whereas other symptoms such as hypomimia (p < 0.0001), speech problems (p < 0.0001), rigidity (p < 0.0001), and hypersexuality (p < 0.0001) were more noted in males. Women received a lower levodopa equivalent daily dose (p = 0.002). Perception of quality of life was generally worse in females (PDQ-39, p = 0.002; EUROHIS-QOL8, p = 0.009). After the two-year follow-up, the NMS burden (Non-Motor Symptoms Scale total score) increased more significantly in males (p = 0.012) but the functional capacity (Schwab and England Activities of Daily Living Scale) was more impaired in females (p = 0.001). Conclusion: The present study demonstrates that there are important sex differences in PD. Long-term prospective comparative studies are needed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results